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Polymers with specific folded conformations — termed “foldamers” — lend themselves to 
a range of potential applications in therapeutic development and biomedical and material sciences.  
One promising approach to foldamer design is to incorporate a combination of unnatural building 
blocks that retain a peptide’s natural side chains while altering the backbone upon which the side 
chains are displayed. This creates a peptide variant with a heterogenous backbone and native-like 
folds and functions.  
The focus of this dissertation is on recent work towards expanding the scope of 
heterogeneous backbone design strategies and consists of two main goals. The first goal is to mimic 
the tertiary structure of a single zinc finger domain (the third finger of Specificity protein 1, Sp1-
3). This expands design strategies past simple tertiary structures and presents dynamic challenges 
such as retaining a precise metal coordination site. Data shown here indicate that appropriately 
designed alterations can allow for a tertiary structure that is superior to the native backbone in the 
context of folded stability and ligand binding. 
The second goal discussed in this work is two part: 1) to investigate if the increase in folded 
stability seen with single domain Sp1-3 backbone variants is generalizable to other Cys2His2 zinc 
finger sequences and 2) to synthesize a multi-domain zinc finger protein through native chemical 
ligation. Each of these aims attempts to push towards the longer-term goal of gaining a better 
understanding of how backbone alterations impact DNA binding in multi-domain zinc fingers.  
Expanding the Scope of Heterogeneous Backbone Designs to Include Single- and Multi-
Domain Zinc Finger Proteins 
Kelly L. George, PhD 
University of Pittsburgh, 2018
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1.0  INTRODUCTION 
A portion of this chapter has been published in: 
George, K. L.; Horne, W. S. Foldamer Tertiary Structure through Sequence-Guided Protein 
Backbone Alteration. Acc. Chem. Res. 2018, 51(5):1220-1228  
 
and is used with permission of the publisher. 
1.1 PROTEIN DESIGN BACKGROUND 
 
The intricacy of protein structure belies a remarkable simplicity in covalent connectivity. 
From an alphabet of just 20 α-amino acids arranged in chains of varying sequence and length, 
countless complex folds and functions emerge. Nature accomplishes this feat by placing protein 
covalent structure (primary sequence) at the root of a hierarchy of higher-order structure that 
results from defined non-covalent intra- and inter-chain contacts. This hierarchy consists of local 
folding motifs (secondary structure), ordered arrangements of such motifs in larger domains 
(tertiary structure), and associations of folded chains (quaternary structure). Chemists have long 
sought to recreate protein-like structural hierarchies in oligomers with backbones that differ from 
natural α-peptides, termed “foldamers”.1 Research on this subject dating back >20 years has shown 
that a variety of artificial backbones can support ordered folds.1-3 Progress toward secondary 
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structure in short chains gave way to quaternary assemblies based on these motifs. In looking 
toward the goal of complex protein-like tertiary folding patterns, a key barrier became apparent. 
How does one design, from scratch, both backbone connectivity and side-chain sequence that will 
support multiple different secondary structures and their defined packing in a single chain?  
Two developments were key to overcoming the above barrier. First was the recognition 
that, while proteins are homogeneous-backbone polymers with variable side chains, a foldamer 
can have a “heterogeneous backbone” that blends monomers differing in both backbone 
connectivity and side-chain identity.4 Second, when one or more α-residues in a biological 
sequence are replaced by an artificial backbone unit compatible with the native fold, as detailed 
further below, the resulting artificial oligomer can mimic the fold and function of the native 
sequence. Taken together, these ideas lead to a view of a protein as having two orthogonal 
sequences: a sequence of side chains and a sequence of backbone units displaying those side 
chains.  
In this dissertation, I describe my work leveraging the above precedent to develop design 
principles for constructing heterogeneous-backbone foldamers that adopt the complex tertiary 
structure and metal binding environment of zinc fingers. I review precedent that informed these 
efforts, survey key results obtained, and look to the future potential applications of 
peptidomimetics. 
Chemists have long been interested in the macromolecules that underlie the most basic 
aspects of human biology. Attempts to understand and even improve upon the folding and binding 
of proteins has been at the forefront of chemistry for decades. Seeing the importance of peptide 
and protein structure, chemists also sought to design methods towards structural mimicry with 
both natural and unnatural moieties and an eye on potential applications as diagnostic and 
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therapeutic tools.5 Designed polymers with specific folding conformations are termed 
“foldamers”.6 Since the term was defined in 1998, the pursuit of foldamer designs has grown into 
a large field with a common pursuit of mimicking biopolymer folds and functions as vast and 
complex as those found in nature.  
Success in protein mimicry by foldamers began with the most common secondary structure 
in natural proteins: helices.7 Foldamers with helical folding propensity have been formed by 
homogeneous repeats of both -peptoids (with side chains attached to nitrogen rather than the a 
carbon) and short -peptides (with an additional carbon in the backbone).8,9 Varying the 
substitution patterns of - and  residues to create a heterogeneous backbone (Figure 1) along a 
helix has also led to a better understanding of helical stability and side chain projection.10,11,12,13  
 
Figure 1. Key differences between a polypeptide consisting of a homogeneous backbone and heterogeneous 
backbone.  
 
Backbone engineering of natural helical sequences has proven a powerful way to create 
protease-resistant analogues with native-like folds and molecular recognition capabilities.14 
Among the most widely used building blocks to this end are Cα-methylated α-residues such as Aib 
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and acyclic β-residues (e.g., β3) (Figure 2). Incorporation of these monomers at one site per turn 
of an α-peptide helix leads to heterogeneous backbones that can fold to form quaternary assemblies 
encoded by the side-chain sequence of the prototype, including homomeric helix bundles15,16 and 
heteromeric complexes with protein receptors.17,18  
 
 
Figure 2. Native  residue alongside a selection of backbone modified analogs 
 
To study β-sheet folding, β-hairpin model systems were used to identify monomers, such 
as such as D-Pro and Aib, that induce a stable turn in short peptides.19,20 These modifications are 
particularly effective when paired with Gly at the i+1 position. Later studies showed the non-
canonical amino acid Orn can promote a tight turn when the polypeptide chain is propagated from 
the side-chain amine (in this context, Orn is a δ-residue and replaces two α-residues in the native 
turn).21 Of note, some of the above modifications as well as other more exotic moeties had been 
examined in protein tertiary fold contexts.22-26 
As for backbone alterations to β-strands, many disrupt hydrogen bonding. One example is 
the introduction of a methyl group on the backbone amide nitrogen (α→N-Me-α substitution). This 
was used to engineer a variant of the protein interleukin 8 that retained a native-like fold but was 
unable to associate via the β-sheet interface found in the native dimer.27 Another established 
strategy for β-sheet backbone modification was the replacement of extended peptide segments 
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with aromatic amino acids. The resulting monomer can display hydrogen bond donor and acceptor 
moieties such that one face of the strand is complementary to a native α-peptide, while the other 
is blocked. Such selective hydrogen bond disruption lends substantial credence to the utility of 
advancing heterogenous backbone designs as these modifications have proved instrumental in 
revealing structure and assembly mechanisms of amyloidogenic sequences28 and developing 
inhibitors of amyloid formation.29-31 Cα,Cα-dialkylated residues of increased steric bulk relative to 
Aib can also promote extended backbone conformations and cap growing sheet-based 
aggregates.32  
A drawback to backbone modifications that disrupt hydrogen bonding in a β-strand is 
incompatibility with incorporation at an internal position of a larger β-sheet. Given the prevalence 
of such motifs in proteins, alternative substitution strategies were also evaluated by my previous 
lab mates. Initial efforts focused on β-residues, as these had proved so versatile in helices. Thus, a 
systematic comparison was completed of β-residues with varied backbone stereochemistry, 
substitution pattern, and ring constraint for the ability to promote β-sheet folding at cross-strand 
positions in a β-hairpin host.33 The results showed that some β-residue classes (e.g., β3) supported 
native-like folds; however, α→β substitution altered the display of side chains on residues flanking 
the modification. It was then established that the same monomer types could be used in alternate 
substitution patterns (αα→β, αα→ββ), resulting in heterogeneous backbone sheets that displayed 
side chains in a native-like fashion.34 A cyclically constrained γ-residue, cis-1-amino-3-
cyclohexanecarboxylic acid (ACC), was shown as a strong sheet stabilizer compatible with 
placement at internal β-strands.35 Thus, α→γcyc substitution at two sites in a host hairpin led to a 
native-like folded state and a folding free energy superior to the natural backbone.34 Although the 
above investigations were carried out in two-stranded hairpins, high-resolution structures obtained 
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suggested the modified backbones would support hydrogen bonding as part of β-sheets in larger 
proteins. 
The precedents outlined above on the mimicry of individual secondary structures by 
backbones in which one or two α-residues is replaced by some artificial counterpart set the stage 
to examine combinations of such modifications in larger, more complex tertiary folds. When I 
joined the Horne Lab, colleagues had begun applying backbone alterations strategies to the tertiary 
structure of the B1 domain of Streptococcal protein G (GB1)(Figure 3).36 This data set has led to 
improved understanding of how to design effective secondary structure mimics, an appreciation 
of the interplay among varied backbone modifications in a protein context, and insights into 
structural and thermodynamic consequences of backbone alteration. This work showed that the 
loops, helix, sheet, and turns of GB1 could be individually modified without abolishing tertiary 
folding, although stabilities of heterogeneous-backbone variants were slightly to somewhat 
compromised.36 Individual modifications (α→β3 substitutions in helix and loops, α→N-Me-α in 
the sheet, α→D-Pro/Aib in the turns) were then combined into a single variant. The resulting 
protein, in which ~20% of the residues in the prototype were replaced, retained a cooperative 
unfolding transition but was significantly less thermodynamically stable than the native.  
 7 
 
Figure 3. Mimicry of GB1 by heterogeneous backbones. (A) Sequence and crystal structure (PDB 2QMT) of 
wild-type GB1. (B) Some backbone modifications made to GB1, grouped by secondary structure context. All 
panels are from published crystal structures of GB1 variants (PDB: 5HFY, 5HI1, 4OZB, 4OZC, 4KGR, 
4KGS, 4KGT), except data for the PEG-modified loop (snapshots from a molecular dynamics simulation) and 
the γcyc-modified sheet (NMR structure of a hairpin peptide derived from GB1). Reprinted with permission 
from George, K. L.; Horne, W. S. Foldamer Tertiary Structure through Sequence-Guided Protein Backbone 
Alteration. Acc. Chem. Res. 2018, 51(5):1220-1228 Copyright 2018 American Chemical Society 
 
 
Collectively, a growing body of results by our lab and others spanning multiple protein 
systems suggests there is a great deal of plasticity with respect to the backbone chemical structures 
upon which sequence-encoded tertiary folds can manifest. Moreover, these efforts suggest 
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sequence-guided backbone alteration as a broadly applicable strategy for generating foldamers 
with complex tertiary folding patterns (Figure 4).  
 
Figure 4. Overview of design principles for sequence-guided protein backbone alteration. Each quadrant 
presents a canonical secondary structure with a chemical representation and example from a folded protein 
(PDB: 2QMT) for the native alongside select replacement strategies shown viable in tertiary fold contexts. 
Adjusted with permission from George, K. L.; Horne, W. S. Foldamer Tertiary Structure through Sequence-
Guided Protein Backbone Alteration. Acc. Chem. Res. 2018, 51(5):1220-1228  Copyright 2018 American 
Chemical Society 
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A majority of natural proteins require specific tertiary or quaternary structures for 
biological function.37 Yet at the onset of my research, examples of unnatural oligomers that mimic 
higher order protein folds beyond those discussed above were limited as the complexity of the 
target fold increases. An important unmet aim in heterogeneous backbone designs of foldamer 
research still existed: mimicry of a tertiary structure with native ligand binding and potential 
biomolecular interaction.  
1.1.1 DNA Recognition by Designed Proteins 
With the growing understanding that a number of diseases, including cancer, originate with 
the misregulation of transcription factors, designed synthetic agents capable of reproducing DNA 
recognition have been developed with increasing sophistication. Miniaturized models of 
transcription factors (both peptidic and small molecule) have been shown to replicate DNA binding 
properties along the major groove but design with specific binding and high affinity have proved 
challenging.38,39,40 Many designs are based on basic Leucine Zipper Proteins (bZIPs), which bind 
DNA through the N-terminal basic region of a leucine zipper dimer motif (Error! Reference 
source not found.).41 It was shown that the leucine zipper portion (highlighted in green in Error! 
Reference source not found.) could be replaced with various linkers including disulfide bonds, 
an array of transition-metal complexes and many other moieties. From this work it was found that 
simply linking the two helices together was not sufficient to facilitate predictable DNA recognition 
and that the identity and geometry of the linker greatly influenced the binding affinity and sequence 
selectivity.42-45 
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Figure 5. A) Structure of Leucine Zipper Proteins (bZIPs) bound to DNA. B) Designed variant of 
Leucine Zipper Protein with various linkers. Reprinted with permission from Sonia, B.; David, B.; Diego, G. 
P.; Miguel, V. L.; Eugenio, V. M., European Journal of Organic Chemistry 2018 (3), 249-261 Copyright 2018 
Wiley Materials  and  with permission from Ellenberger, T. E.; Brandl, C. J.; Struhl, K.; Harrison, S. C., Cell 
1992, 71 (7), 1223-1237. Copyright 1992 Elsevier 
 
Another and more recent approach includes designs that combine transcription factor 
motifs with short minor groove anchors. Linking together a short minor groove binding tail from 
the Serum Response Factor to the DNA helix of Elk1 was not only found to bind DNA but also 
was readily internalized into the nuclei of lung adenocarcinoma cells inducing a response and 
downregulating its targeted gene.46  
1.1.2 DNA and RNA Recognition by Foldamers 
Several foldamer designs have been made to mimic DNA and RNA recognition of natural 
motifs. For example, homogeneous β-peptides in the form of amphiphilic 14-helices have been 
!!
A)
B)
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designed by Seebach to mimic the binding pattern of eukaryotic transcription factors along the 
major groove of DNA.47 Additionally, foldamer designs with -peptide/-peptoid chimeras and 
homogeneous β-peptides have each been shown to mimic the HIV tat protein native recognition 
of RNA and even inhibit the infectivity of herpes simplex virus.48-50  
 
1.2 ZINC FINGER BACKGROUND 
1.2.1 Zinc Finger Structure and Function 
First characterized in 1983, zinc fingers (ZFs) were originally identified through studies in 
the African clawed frog (Xenopus laevis) in which the interaction between the protein transcription 
factor IIIA (TFIIIA) and 5S rRNA necessitated zinc ions for specific DNA binding.51 Six years 
later, studies showed that removal of zinc from TFIIIA resulted in a loss of both DNA binding and 
tertiary fold.52 In the absence of zinc, the peptide returned to a random coil conformation. Previous 
to this, metal ions were known only to play functional roles — in enzyme catalysis, for example. 
The above studies confirmed that zinc could also play the structural role of maintaining a tertiary 
fold.53  
This stabilization of the precise tertiary structure is crucial for transcription factors as it 
enables side chains to reside in the specific three dimensional space required for selective nucleic 
acid binding. In the case of zinc fingers, it is a tetrahedral coordination of metal with various 
combinations of cysteines and histidines (Cys4, Cys3His, Cys2His2) which stabilize the tertiary fold 
along with a hydrophobic core. Individual zinc fingers consist of around 30 residues and are linked 
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together in sets of three to nine to create tandem-binding motifs that can span along wide stretches 
of protein or nucleic acids. While the number and order of metal binding residues had traditionally 
been used as a classification system, more recently zinc fingers have begun to be classified by their 
overall folding motif.54 Common folding motifs include the treble clef, zinc ribbon and the 
classical Cys2His2 motif (Figure 6).  
 
Figure 6. Main types of zinc finger motifs. Zinc Ribbon (PDB: 1PFT), Treble Cleft (PDB: 1HC7) and 
Cys2His2 (PDB: 1VA3) 
 
In Cys2His2 zinc fingers, residues along the recognition helix are numbered starting with 
the C-terminal end of the helix at position 1. DNA contacts are made by residues at positions -1, 
+3 and +6 along the helix to the coding strand of DNA and by residue +2 to the noncoding strand 
of DNA (Figure 7).55 Each finger contacts a 4-base pair site that overlaps with those of the adjacent 
fingers. 
Cys His Treble CleftZinc Ribbon 22
 13 
 
Figure 7. View of a Cys2His2 zinc finger and its contacts with DNA through residues at helical positions -1, 2, 
3 and 6. Reprinted with permission from Klug, A., The Discovery of Zinc Fingers and Their Applications in 
Gene Regulation and Genome Manipulation. Annual Review of Biochemistry, 2010. 79(1): p. 213-231.  
 
Interest in better understanding the structure and function of zinc fingers is rooted in the 
clinical association of mutations with developmental abnormalities and cancer.56-59   Non aromatic 
substitutions within the hydrophobic core, for example, are known to impair DNA binding and 
transcriptional activation in vitro and have been associated with cancer and birth defects in vivo.56 
One study investigated the point mutation on the human tumor suppressor WT1 gene that produces 
a zinc finger with a Leu in place of the consensus Phe and results in Fraiser syndrome, a rare 
genetic disorder. Synthesis and analysis via circular dichrosim (CD) and  isothermal titration 
calorimetry (ITC) demonstrated the consensus Phe at the site in question, typically considered a 
integral part of the hydrophobic core, is necessary for precise DNA interactions. Without it, 
aberrant DNA interaction results in phenotypes correlated to Fraiser syndrome.60   
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1.2.2 Zinc Finger Mimics and Engineering Precedents 
The folding and DNA binding propensity of a zinc finger as well as its affinity for zinc are 
all correlated to the placement of consensus side chains; modification of the structure is generally 
a delicate endeavor.61 Nonetheless, a diversity of approaches to mimicking the structure, metal 
binding and DNA binding of zinc fingers has been demonstrated since the first crystal structure 
was published in 1991.62 The design of ZFs with specific DNA binding propensities was pioneered 
by Klug and Berg.63,64 Various approaches were made to create ZF libraries exploring the coding 
relationship between zinc fingers and DNA.65,66 Work focusing on zinc finger point mutations67, 
sequence and length alterations to the linker68 (residues connecting each zinc finger), and 
substitutions in the hydrophobic core60 also contributed to understanding of base pair recognition. 
Other designed mimics of zinc fingers have taken the core  structure as a template that can be 
built upon to create a variant of the  motif in the absence of a metal ion.69,70 Sequences 
identified by computational processes to resemble the structure of zinc fingers have also been 
synthesized and characterized.71 Though, the computationally predefined stability does not always 
accurately predict the experimentally stability.72  
1.2.3 Zinc Finger Nucleases 
The combined knowledge of zinc finger engineering and the characterization of the 
dimerizing restriction endonuclease FokI, together, ushered in the era of targeted, site-specific 
gene editing with the pioneering design of Zinc Finger Nucleases (ZFNs).70,73 Until the late 2000’s, 
ZFNs were the only gene modification nucleases used in clinical trials (ClinicalTrials.gov 
identifier numbers: NCT02388594, NCT00842634, NCT01044654, NCT01252641, 
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NCT02225665, NCT02500849). Many clinical trials with ZFNs are still ongoing. Yet, often the 
success of ZFNs in vitro has been followed by a lack of genome modification in vivo.74   
While RNA-guided nuclease gene editing with CRISPER/Cas9 has shifted attention to a 
simpler method that does not require protein engineering,73 the gap between the excitement behind 
ZFNs and resulting level of success deserves consideration. The majority of engineered designs of 
ZFNs focused on the affinity and selection of DNA binding whereas the impacts of sequence 
alterations on critical aspects such as kinetics and thermodynamic stability were rarely 
considered.75 Along with this, the design of sequences that bind to predicted DNA bases proved 
far more challenging than anticipated and interactions between zinc fingers had a greater impact 
than previously expected.73 It is plausible that the engineered ZFNs failed to reach their target 
sequence because the balance between protein folding, protein scanning and protein binding was 
not entirely understood or taken fully into account.75 Likewise, the complexity of the protein-
protein, protein-DNA, and protein-zinc interactions were equally unappreciated. The need for a 
more thorough comprehension of the downstream impacts imbedded in sequence alteration for 
complex biological processes such as this underlies the importance of work within the foldamer 
field. Continued systematic studies of the impacts of protein sequence design with detailed analysis 
of kinetic and thermodynamic consequences could potentially allow future pursuits to avoid the 
pitfalls faced by ZFNs.  
 While work discussed in this dissertation does not specifically extend into a space where 
these pitfalls could be addressed in their entirety, the data and discussions herein do represent a 
step towards a better understanding of the complexities of natural and unnatural zinc fingers.  
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2.0  HETEROGENEOUS BACKBONE MIMICS OF A ZINC FINGER DOMAIN 
A portion of this chapter has been published in: 
George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger 
Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. 
 
and is used with permission of the publisher. 
2.1 INTRODUCTION 
 
Figure 8. Backbone Alterations of Sp1-3 Zinc Finger 
 
A variety of oligomeric backbones with compositions deviating from biomacromolecules 
can fold in defined ways. Termed “foldamers,” these agents have diverse potential 
applications. A number of protein-inspired secondary structures (e.g., helices, sheets) have been 
produced from unnatural backbones, yet examples of tertiary folds combining several 
secondary structural elements in a single entity are rare. One promising strategy to address this 
challenge is the systematic backbone alteration of natural protein sequences,  through which a 
subset of the native side chains is displayed on an unnatural building block to generate a 
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heterogeneous backbone. A drawback to this approach is that substitution at more than one or 
two sites often comes at a significant energetic cost to fold stability. Here we report heterogeneous-
backbone foldamers that mimic the zinc finger domain, a ubiquitous and biologically important 
metal-binding tertiary motif, and do so with a folded stability that is superior to the natural protein 
on which their design is based. A combination of UV−vis spectroscopy, isothermal titration 
calorimetry, and multidimensional NMR reveals that suitably designed oligomers with >20% 
modified backbones can form native-like tertiary folds with metal-binding environments identical 
to the prototype sequence (the third finger of specificity factor 1) and enhanced thermodynamic 
stability. These results expand the scope of heterogeneous-backbone foldamer design to a new 
tertiary structure class and show that judiciously applied backbone modification can be 
accompanied by improvement to fold stability.  
The characteristic of proteins that enables their varied and sophisticated biological roles is 
the ability to fold into compact, well-ordered conformations encoded by amino acid sequence. 
Biomacromolecules are not unique in having the capacity for sequence-encoded folding, and 
diverse oligomeric backbones of alternate chemical compositions can show discrete folding 
propensities. The bulk of research on this class of molecules, termed “foldamers,”6 has focused on 
secondary structures (helices, sheets, and turns) that are either inspired by motifs found in nature 
or completely abiotic in origin.2,3,76-81 More recent work has sought to create unnatural backbones 
that mimic target folds with increased intricacy, such as multi-helix quaternary assemblies,15,82-84 
multi-stranded sheets,85-87 and unimolecular tertiary structures.36,88-90 The design of such molecules 
remains a significant challenge, the magnitude of which scales with the complexity of the desired 
fold.  
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While tertiary structure is crucial to protein function, so too in many cases is the ability to 
bind a cognate ligand. It has been estimated that a third of all proteins bind to some metal ion and 
half of enzymes require a specific metal to function.91 Despite this ubiquity in nature, examples of 
metal binding in foldamers represent only a small fraction of the many unnatural folded units 
reported to date.92 Most examples have been based on oligomers with metal-coordinating 
backbones,93-96 while some have shown metal binding is possible in designed oligomers with 
peptide-based backbones closer to those found in nature.97-106 
A powerful strategy for designing molecules that mimic sophisticated protein folds is the 
systematic backbone alteration of biologically derived sequences — inducing a natural 
arrangement of side chains to manifest a native-like fold on a backbone consisting of a blend of 
natural and unnatural building blocks.107 Such heterogeneous-backbone oligomers can resist 
degradation by protease enzymes, depending on the nature of the modification,108 and have 
potential applications in areas ranging from therapeutic109 and diagnostic110 to entirely novel 
functions.111-113 Foundational work led to robust design principles for mimicry of α-helix and β-
sheet secondary structures by this approach. More recent efforts have expanded to tertiary structure 
contexts, specifically a disulfide-cyclized helix-turn-helix motif derived from Staphylococcal 
protein A110,114 and the α/β tertiary fold of the B1 domain of Streptococcal protein G 
(GB1).36,87,115,116  
As noted above, protein backbone alteration can be accompanied by functional benefits; 
however, these benefits are almost always offset by compensating penalties to folded stability 
when more than one or two residues are altered.117-121 The degree to which these observations may 
prove general vs. system dependent is not clear from precedent. Is it the case that natural side-
chain sequences, finely honed by evolution to encode folding in an α-peptide context, will always 
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function best on a natural backbone? Alternatively, is it possible that certain significantly modified 
backbones may surpass nature in the capacity to manifest complex folds encoded by biologically-
derived sequences? The best way to answer these questions is to expand heterogeneous-backbone 
foldamer design to a wider array of tertiary folds. Here, we report efforts to target the zinc finger, 
a ubiquitous motif in nature where folding and metal binding are intimately coupled. Examination 
of backbone-modified variants of a biologically derived domain found oligomers with >20% 
unnatural content that are identical to the native in folded structure and superior in folded stability.  
Zinc fingers make up the largest class of eukaryotic proteins122 and are estimated to be 
encoded by 3% of human genes.55 The folding of these motifs is driven by and entirely dependent 
upon binding to a Zn2+ ion. Zinc finger domains are typically arrayed in tandem as part of larger 
DNA-binding proteins, giving rise to exquisite sequence-specific recognition of DNA through 
docking into the major groove of the double helix. As a modular protein domain, there has been a 
great deal of progress in designing and linking individual zinc fingers to engineer larger DNA-
binding proteins able to modulate expression of specific genes.123 Notable examples include 
designer zinc fingers that inhibit the replication of HIV124 and others that stimulate angiogenesis.125 
Moreover, the inherent cell permeability of zinc fingers has paved the way for their use as a 
delivery system.126  
We chose the third finger of specificity factor 1 (Sp1-3) as the prototype zinc finger in 
which to investigate sequence-guided backbone modification detailed below. Sp1-3 is a classical 
example of the Cys2His2 zinc finger discussed in the introduction (Figure 9). In the presence of 
Zn2+, the 29-residue Sp1-3 adopts a ββα tertiary fold supporting a metal coordination site 
consisting of two Cys residues and two His residues (Cys2His2, Figure 9).
127 The fold is further 
stabilized by a conserved hydrophobic core consisting primarily of two Phe and one Leu residue. 
 20 
Based on Sp1-3, peptide 1 differs from the native sequence only in a Phe2→Tyr substitution made 
to facilitate spectroscopic concentration determination. Peptide 1 (Figure 9) served as the starting 
point for backbone modification and as a control for experiments aimed at characterization of 
folding and metal binding in the single domain zinc finger mimics. 
 
  
Figure 9. (A) Primary sequence and secondary structure map of the Sp1-3 zinc finger, with metal-
coordinating residues underlined. (B) NMR structure of Sp1-3 (PDB 1SP1) with close-up views of the 
Cys2His2 metal-binding environment (C) and β-turn between the two strands (D). Reprinted with permission 
from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary 
Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
To explore the relationship between backbone composition and folding, we prepared eight 
analogues (2-9) of the parent Sp1-3 sequence (Figure 10). Collectively, these oligomers 
incorporate a variety of unnatural building blocks in place of a subset of the α-residues in 1: D-α-, 
N-Me-α-, Cα-Me-α-, β-, and δ-residues. In terms of composition, 21-25% of the backbone in each 
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sequence is altered. Design rationales behind each oligomer are detailed below. Relative to peptide 
1, an additional Met12→Nle mutation was made to reduce complications arising from oxidation of 
this residue during synthesis, purification, and characterization. Peptides 1-9 were synthesized by 
microwave-assisted Fmoc solid-phase methods and purified by reverse-phase HPLC; the identity 
and purity of each were confirmed by MALDI mass spectrometry and analytical HPLC. 
 
 
 
Figure 10. Primary sequence of peptide 1 and backbone-modified analogues 2-9. Bold residues indicate 
positions where the backbone is altered. For residue types with “R” groups, the identity of the side chain is 
that of the corresponding α-residue denoted by the single letter code found in the sequence. Reprinted with 
permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger 
Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
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As a primary assay for folding and metal binding, we carried out UV-vis spectroscopy in 
the presence of Co2+. Substitution of the native Zn2+ ligand in this way gives rise to spectroscopic 
features highly sensitive to the metal-binding environment and is a common tool in the study of 
zinc-binding proteins.128 Thus, we acquired the spectrum of a 100 μM solution of peptide in 20 
mM HEPES, pH 7.0, with a slight excess of Co2+ (Figure 11). The data obtained for 1 are consistent 
with prior published results for Sp1-3, indicating the small sequence change did not alter the 
fold.129 Bands in the 300-350 nm range result from thiolate-to-Co2+ ligand-to-metal charge-transfer 
transitions with intensities correlating to the number of coordinating Cys residues.130,131 Diagnostic 
d-d absorption bands in the 500-700 nm region arise from a tetrahedral cobalt(II) species, and the 
shape, intensity, and position of these peaks are diagnostic of coordination residue type and 
number.132,133 Thus, the observation of peaks at 640 nm and 570 nm in a 3:1 ratio for 1 is consistent 
with the expected Cys2His2 tetrahedral metal binding site.  
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Figure 11. Interaction of 1-9 with Co2+ as determined by UV-vis spectroscopy. Measurements were carried 
out in a 1 cm path length cell at 100 μM peptide concentration in 20 mM HEPES pH 7.0 with 1.3 equiv of 
Co2+ (2 equiv Co2+ for peptide 5). Reprinted with permission from George, K. L.; Horne, W. S. 
Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 
7931-7938. Copyright 2017 American Chemical Society 
 
The design of analogues 2 and 3 was based on our prior published observations for 
backbone modification strategies most effective at mimicry of the GB1 tertiary structure.36,87,115,116 
A single α→N-Me-α substitution was made in each strand of the hairpin segment at sites where 
the newly introduced methyl group should project toward solvent. α→β3 substitutions were 
incorporated in each turn of the α-helix, such that added CH2 groups in the backbone would reside 
opposite the hydrophobic core of the tertiary fold. For both the N-Me-α- and β3-residues, the native 
Sp1-3 side chain was retained at each point of modification. In place of the central residues of the 
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β-turn (Pro5Glu6), we incorporated one of two unnatural turn inducers in the form of an XxxGly 
sequence, where Xxx is either D-Pro or the Cα-Me-α-residue Aib.  
UV-vis spectra obtained for 2 and 3 in the presence of Co2+ showed that the signal at ~300 
nm was retained in each case, suggesting interaction between Cys residues and the metal. 
However, the absence of peaks in the visible region indicated the well-defined metal coordination 
environment of native Sp1-3, and thus the tertiary fold, was abolished upon backbone 
modification.  
In considering the inability of 2 and 3 to mimic the parent zinc finger fold, several 
considerations drew our attention to the turn region. First, the central turn is located directly 
between two metal-binding residues (Cys4 and Cys7); small changes in local conformation could 
alter alignment of these side chains and their propensity to bind metal in the folded state. Second, 
analysis of the NMR structure of Sp1-3 indicates the backbone reversal is best classified as a 
“double turn,”134 where a type-I turn encompassing Cys4-Cys7 overlaps with a type-VIII turn 
encompassing Pro5-Pro8 (Figure 12). The unnatural turn replacements employed in 2 and 3 are 
proven substitutions for canonical type-I and type-II turns in diverse systems;19,20 however, they 
tend to promote mirror image type-I’ and II’ turn conformations that may be incompatible with the 
overlapping type-VIII turn directly following in Sp1-3. Finally, the side chain of Glu6 is lost in the 
two analogues. This residue is found near the zinc ion in the NMR structure, where it may 
contribute as a second sphere ligand and/or stabilize the metal binding site through interaction with 
His.24 Ideal phi and psi angles for each of the  turn types discussed are plotted in pale colors on 
the Ramachandran plot in Figure 12b along with the angles of residues Pro5, Glu6, and Cys7 in 
Sp1-3.  
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Figure 12. A. Sp1-3 Turn  (PDB: 1VA3) B. Ramachandran plot depicting the tandem type-I, type-VIII double 
turn in Sp1-3. Idealized values are shown for residues i+1 (symbol) and i+2 (end of line) in the canonical turn 
types indicated, 1 alongside the conformation of residues Pro5, Glu6, and Cys7 in Sp1-3.  Reprinted with 
permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger 
Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
To test the hypothesis that the modified turns were responsible for the inability of 2 and 3 
to fold, we examined peptide 4. This oligomer retains most of the backbone alterations present in 
2 and 3 but restores the turn to its native composition. In the UV-vis assay with Co2+, peptide 4 
showed spectral features virtually identical to the parent domain 1. This result, along with further 
experiments detailed below, provides compelling evidence for a native-like tertiary structure.  
With evidence that the Aib-Gly and D-Pro-Gly segments in 2 and 3 were incompatible with 
the Sp1-3 fold, we explored other modifications to the turn region. Peptides 5 and 6 were designed 
to examine whether the turn conformation might be the leading determinant against folding. Each 
incorporates a δ-residue as a dipeptide replacement in the center of the type-II turn encompassing 
Pro5-Pro8. Peptide 5 employs ornithine connected via its side chain to the preceding residue (δO), 
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a well-established turn inducer.21 Peptide 6 is an analogue of 5 with a less constrained, achiral δ-
residue (δX). We reasoned the enhanced flexibility of δX relative to δO might help the two flanking 
Cys residues adopt an appropriate metal binding geometry. Peptides 7 and 8 restore the native Glu6 
side chain to 2 and 3, respectively, and were designed to test the hypothesis that the loss of this 
side chain accompanying backbone modification was responsible for the inability to fold.  
Analysis of the Co2+ binding characteristics of peptide 5-8 by UV-vis showed no evidence 
of a tetrahedral metal coordination environment and, thus, argues against any of these oligomers 
adopting a native-like tertiary fold. As with 2 and 3, ligand-to-metal-charge-transfer transitions are 
observed in all cases; however, none of the modified backbones show peaks characteristic of 
Cys2His2 tetrahedral coordination. Peptide 8 with the Aib-Glu turn did show some signal ~640 nm, 
but the low intensity of this peak and broad background across the visible spectrum suggest 
significant heterogeneity in any interaction of the peptide with Co2+.  
Collectively, the inability of any of the turn modifications examined to be tolerated in Sp1-
3 highlights the challenges of chemical protein backbone alteration. Nevertheless, we were 
heartened by the promising results obtained for peptide 4 with modifications throughout the helix 
and hairpin. To further explore relationships between backbone composition and folding in the 
zinc finger motif, we prepared peptide 9, an analogue of 4 where two of the β3-residues in the helix 
are replaced by the Cα-Me-α residue Aib. We recently reported a thermodynamic comparison of 
the helical folding propensity of β3- and Cα-Me-α-residues in the GB1 tertiary fold and were 
motivated to see to what degree those observations might hold in a fundamentally different 
structural context.116 The data obtained in the Co2+ binding assay showed that peptide 9 supports 
a metal coordination environment indistinguishable from both analogue 4 and the native backbone 
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(1). Thus, we advanced peptides 1, 4, and 9 to experiments aimed at a more thorough 
characterization of folding. 
2.2 FOLDING AND METAL BINDING THERMODYNAMICS 
The thermodynamics behind protein folding has long been an area of intense interest. Both 
side-chain mutations and backbone modifications can often have dramatic thermodynamic 
impacts, and a solid understanding of the fundamentals driving these changes is an important 
precursor to understanding folding behavior.  
For most protein folding events, thermodynamic contributions towards the overall free 
energy consist of enthalpic drive and entropic opposition.135 Main contributors are the hydrophobic 
effect, protein solvation/desolvation, and the formation of hydrogen bonds. The hydrophobic effect 
describes the packing of nonpolar residues within the peptide core and in the process releases 
highly organized water molecules (desolvation effect), which contributes to the entropic drive 
toward the folded state. Counter to this is the entropic penalty conferred due to the loss of torsional 
freedom as the backbone transitions from a disordered unfolded ensemble to an organized folded 
state. The multitude of hydrogen bonds also greatly contributes enthaplically. The interplay of 
these factors creates the delicate balance described as enthalpy-entropy compensation (EEC).136 In 
most cases, a folded conformation is reached which is more stable than the denatured state by 
around 5-15 kcal/mol.135  
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2.2.1 Thermodynamics of Folding in Heterogeneous Backbones 
The folding thermodynamics of heterogeneous backbones is not nearly as well studied as 
that of natural peptides and proteins. One building block that has been studied to some extent is 
the unnatural residue amino isobutyric acid (Aib). Aib resides in restricted Ramachandran space 
and has been shown to enhance the thermodynamic stability of a folded protein when replacing an 
alanine residue.137 This is likely due to both the decreased entropic penalty caused by rigidity in 
both denatured and folded state as well as an increased enthalpic drive through helix stabilization.  
While assumptions can be made to predict potential impact of backbone modification on 
such events as peptide desolvation, conformational freedom and intramolecular interactions upon 
folding, caution must be taken, as many of the thermodynamic consequences of altering the 
backbone may not be apparent. For example, the increased conformational freedom that 
accompanies substitution with   residues might be expected to increase the entropy of the 
unfolded state and create a greater penalty for folding. Previous studies from our group in the 
protein GB1, however, have observed the opposite:   residue substitution incurs an entropic drive 
for folding.115 It is hypothesized that this is due to the altered solvation properties of the unfolded 
peptide that contains more hydrophobic regions and thus forces additional order in the solvent.  
This ordered solvent lessens the entropy of the unfolded state (compared to solvent interacting 
with a native sequence) and thus creates an entropic advantage to dismantle the ordered cages of 
solvent and drive folding.  
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2.2.2 Thermodynamics of Zinc Finger Folding and Binding 
An additional aspect to consider when analyzing the thermodynamics of zinc finger 
folding/binding, in particular, is the transition of zinc from a hydrated complex to a peptide-bound 
state (Figure 13). The enthalpy associated with zinc coordination by cysteine/histidine in 
comparison to the coordination in the zinc hydration shell is one of the largest overall contributions 
driving the zinc finger folding and binding event.  
 
Figure 13. Overall reaction scheme of zinc - Sp1-3 binding. (PDB: 1VA3) At pH 7.4, both the 
cysteines and the histidines of Sp1-3 are mostly in their neutral form prior to folding (pKa = 8.2 and 6.15, 
respectively138) and zinc is in its hydrated state. Upon folding, thiols deprotonate and released protons are 
taken up by buffer. 
 
 
In zinc fingers, folding and metal binding are closely coupled in a single overall process. 
Interestingly, one study aimed to better understand this interplay by uncoupling zinc finger folding 
and binding through the design of several minimalistic sequences consisting entirely of glycine 
apart from a binding site of either Cys4, Cys3His or Cys2His2.139 These unstructured, glycine rich 
sequences teach us little about a true zinc finger system as they lack the torsional restraints that 
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accompany structure. Yet, the analysis of the complexities incurred when binding and folding are 
coupled is beneficial as we consider the thermodynamic comparison of variants to peptide 1 
(Figure 14). Numerous other studies have looked into zinc finger binding and folding yet the 
relative thermodynamic contributions of ZF-metal verses ZF-ZF interactions is still not entirely 
understood.138 What is well understood is the importance of side chain positioning and the 
formation of the hydrophobic core.  
 
 
Figure 14.  Folding events of A) a zinc finger with coupled binding and folding and B) a minimalistic zinc 
finger in which folding is not coupled to binding. ML-Obs = observed metal ligand binding free energy. 
Reprinted with permission from Reddi et al., JACS 2007 129 (42), 12815-12827. Copyright 2007 American 
Chemical Society. 
 
In a series of related sequences with consistent metal binding sites, contributions from 
peptide-metal interactions and accompanying proton transfer to buffer are similar; differences in 
observed energetics within the series are then dominated by differences in folding energetics.61 
Thus, comparison of metal binding thermodynamics between wild-type peptide 1 and analogues 4 
and 9 has the capacity to shed light specifically on the energetic consequences of backbone 
modification in the zinc finger domain. 
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We first examined the binding affinity of each peptide for Co2+ by monitoring the intensity 
of the UV-vis peak at 620 nm as a function of added metal. The resulting binding isotherms (Figure 
15) revealed dissociation constants (Kd) ~2 μM for wild-type sequence 1 as well as backbone-
modified 4 and 9106 (Table 1). These values are comparable to literature precedent for Sp1-
3,129,138,140 indistinguishable within the uncertainty of the measurement, and at the limit of the 
affinity detectable under the conditions of the experiment. Some deviation from the expected curve 
for 1:1 binding stoichiometry was observed in the fitting. This behavior has been previously 
reported for other Cys2His2 zinc fingers and is attributed to a process in which multiple peptide 
chains bind metal competing with the formation of the 1:1 complex.141,142 Based on the relative 
dissociation constants for this competing pathway (Kd2), the expected 1:1 complex dominates at 
all but the lowest peptide:Co2+ ratios.  
 
 
 
 
Figure 15. Co2+ binding isotherms for peptide 1 and backbone-modified analogues 4 and 9 determined by UV-
Vis spectroscopy. Samples consisted of 100 μM peptide in 20 mM HEPES, pH 7.0. Error bars represent 
standard deviation from 3 independent measurements. Lines are the result of fitting to a 1:1 binding model 
with competing formation of a 2:1 peptide:metal complex (see methods for details). Reprinted with 
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permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger 
Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
We next assessed the interaction of peptides 1, 4, and 9 with Zn2+ by isothermal titration 
calorimetry (ITC). Besides confirming the ability of the modified backbones to fold in the presence 
of the native ligand, ITC experiments provide more accurate measurements of energetics for 
folding and metal binding compared to UV-vis titration as well as new information in the form of 
entropy/enthalpy components. ITC results (Figure 16, Table 1) show that the affinity of both 
backbone-modified analogues for Zn2+ is higher than that of parent sequence 1. Consistent with 
prior studies on zinc finger domains, binding stoichiometries (n) were found to be slightly less 
than 1, which we attribute to partial oxidation of Cys residues during the measurement.143 The 
observation that the metal binding affinities, and thus folding free energies, are so similar among 
1, 4, and 9 is significant. In our previous work on analogous backbone modifications in the GB1 
tertiary structure, a comparable fraction of backbone alteration led to a destabilization of the 
tertiary fold by ~8 kcal mol-1.36 Here, backbone modification has an opposite favorable effect on 
folding, with a magnitude as large as 0.5 kcal mol-1 in the case of peptide 4. As the folded state of 
each analogue remains identical to that of the native sequence, we reason that the differences in 
fold stability originate elsewhere along the folding pathway, either in the denatured ensemble115 
or folding intermediates.144 
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Table 1. Thermodynamic Parameters for Metal-Binding Interactions of Peptides 1, 4, and 9 with Co2+ and 
Zn2 
 
aDetermined by UV-vis titration with Co2+; Kd and Kd2 are the dissociation constants for 
formation of the 1:1 and 2:1 ligand to metal complex, respectively. bDetermined by ITC with 
Zn2+. Reprinted with permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone 
Foldamer Mimics of Zinc Finger Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-
7938. Copyright 2017 American Chemical Society 
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Figure 16. Isothermal titration calorimetry (ITC) data for the interaction of Zn2+ with peptide 1 and 
backbone modified analogues 4 and 9 in 50 mM HEPES, 100 mM NaCl, pH 7.4. Reprinted with permission 
from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary 
Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
ITC data also provided insights into the thermodynamic trends underlying the observed 
stabilization of the fold upon backbone modification. Like the parent sequence 1, folding and metal 
binding in analogues 4 and 9 are enthalpically driven and entropically opposed. Taking the 
energetic values for 1 as a baseline for comparison (Figure 17), the backbone modifications in 4 
(2 α→N-Me-α; 4 α→β3) have a moderately unfavorable effect on folding ΔH (~0.6 kcal mol-1 per 
substitution) that is more than compensated for by a favorable effect on folding TΔS (~0.7 kcal 
mol-1 per substitution). The above qualitative trend follows that seen upon α→β3 modifications in 
the helix of GB1;115 however, the quantitative balance between parameters differs between the two 
systems.36 The magnitude of the unfavorable ΔΔH in 4 vs. 1 is comparable in GB1 and Sp1-3 yet 
the corresponding favorable ΔΔS is much greater in the zinc finger motif. Two key structural 
dissimilarities between GB1 and Sp1-3 may be responsible for this difference: chain length [56 
residues in GB1 vs. 29 in Sp1-3] and fraction apolar side chains [59% in GB1 vs. 28% in Sp1-3]. 
The favorable entropic impact of additional methylene groups (from α→β3 substitutions) is greater 
in the shorter, more hydrophilic Sp1-3. 
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Figure 17. Summary of changes to the free energy, enthalpy, and entropy for the interaction between the 
indicated peptide and Zn2+ as determined by ITC in 50 HEPES, 100mM NaCl, pH 7.4. Changes are reported 
relative to corresponding parameters for natural backbone 1. Reprinted with permission from George, K. L.; 
Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary Structure. J. Am. Chem. 
Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
In peptide 9, which contains 2 α→Cα-Me-α replacements in place of 2 α→β3 replacements 
in 4, the enthalpic penalty and entropic boost accompanying backbone modification are both 
reduced in magnitude when compared to 4. These data argue that the β3-residues are the primary 
source of both the unfavorable ΔΔH as well as the favorable ΔΔS in the heterogeneous backbones. 
Interestingly, and counter to observations in GB1, the effect of replacing β3-residues with Aib is 
overall unfavorable in the zinc finger. While the origins of this observation are unclear, the impacts 
of α→Cα-Me-α replacement in place of α→β3 replacement in Sp1-3 and GB1 are not solely due to 
a change in backbone composition but a loss of the native side chain as well.  While Ala and Asn 
side chains were altered in the GB1 system, in Sp1-3 Lys and Gln are modified.  
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2.3 HIGH-RESOLUTION STRUCTURAL CHARACTERIZATION OF THE 
FOLDED STATE 
The experiments detailed above all involve measurements related to the interaction 
between the zinc finger and metal. While folding and metal binding are highly interdependent, 
such analyses provide only indirect evidence bearing on the nature of the folded state. For a direct 
assessment of folded structure in the modified backbones and how it compares to the parent zinc 
finger, we subjected peptides 1, 4, and 9 to multidimensional NMR spectroscopy. We acquired 
1H/1H COSY, TOCSY, and NOESY spectra for each peptide at 1.3-1.6 mM peptide concentration 
with 1.2 equiv. ZnCl2 in 9:1 H2O/D2O at pH 7.0 (uncorrected). Comparison of backbone Hα 
chemical shifts for canonical α-residues present in all three sequences (Figure 18) showed 
significant deviations from random coil values and an identical pattern and magnitude of those 
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deviations along the chain. Collectively, these observations argue strongly for a similar folded 
state.  
 
 
Figure 18. Backbone Hα chemical shift deviation from predicted random coil values for peptide 1 and 
backbone-modified analogues 4 and 9 as determined by NMR spectroscopy at pH 7.0 with 1.2 eq. Zn2+. 
Asterisks indicate unnatural residues (no literature random coil chemical shift available for comparison) and 
open circles cases where Hα could not be unambiguously assigned. Reprinted with permission from George, 
K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer Mimics of Zinc Finger Tertiary Structure. J. Am. 
Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American Chemical Society 
 
To evaluate the folds of 4 and 9 at higher resolution, we assigned the majority of backbone 
and side-chain resonances in each and analyzed both local and long-range NOEs. Select short-
range correlations confirmed the secondary structure pattern of the parent domain was retained in 
the modified backbones (Figure 18). Strong sequential i→i+1 Hα-HN cross peaks were observed 
in each strand of the putative hairpin, along with a strong inter-strand Hα-Hα correlation between 
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N-Me-Ala3 and N-Me-Arg10. Near-continuous i→i+1 HN-HN and i→i+3 Hα-HN correlations were 
seen in the expected helical region. In addition to short-range correlations indicative of secondary 
structure, a number of long-range NOEs were observed between the helix and hairpin that were 
consistent with the expected tertiary fold (Figure 19). Root mean square (RMSD) values 
comparing the C- atoms of each of the nine lowest energy structures of peptide 4 to that of the 
previously reported tertiary folded structure for the native Sp1-3 domain are shown in Table 2. All 
root mean square deviations are below 1.5 Å suggesting that each lowest energy conformation of 
peptide 4 is highly similar to the previously reported structure. The ninth lowest energy structure 
shows the lowest RMSD of 1.205 Å while structure 5 shows the highest RMSD of 1.459 Å. 
 
 
 
 
Figure 19. Analysis of the folded structure of 4 and 9 by NMR. (A) Secondary structure maps with select 
short- and medium-range NOE correlations supporting that assignment. (B) Overlay of the 9 lowest energy 
structures of peptide 4 as determined by simulated annealing with NOE distance restraints. Color code for 
carbons matches that in Figure 2. (C) Overlay of the NMR structure of peptide 4 (color) with that of Sp1-3 
(white). Reprinted with permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer 
Mimics of Zinc Finger Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American 
Chemical Society 
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Table 2. RMSD values in comparison to previously reported tertiary structure of Sp13 (PDB: 1SP1). 
  RMSD ( Å ) 
5US3, target_state = 1 1.287 
5US3, target_state = 2 1.325 
5US3, target_state = 3 1.324 
5US3, target_state = 4 1.352 
5US3, target_state = 5 1.459 
5US3, target_state = 6 1.342 
5US3, target_state = 7 1.374 
5US3, target_state = 8 1.252 
5US3, target_state = 9 1.205 
 
To capture a high-resolution picture of the folded state for one of the heterogeneous 
backbones, we tabulated a set of unambiguous inter-residue NOEs for peptide 4 and performed 
simulated annealing with distance restraints derived from NOE intensities. Preliminary 
calculations with just the NOE restraints supported the native-like pattern of secondary structures, 
overall tertiary folding topology, and proximity of Cys4, Cys7, His20 and His24 side chains around 
the expected binding site for Zn2+. We therefore repeated the simulation with additional geometric 
restraints for hydrogen-bonds in the helix as well as the idealized tetrahedral coordination of the 
Zn2+ ion. The resulting ensemble of lowest energy structures showed excellent internal agreement 
and close homology to the reported folded structure for the native Sp1-3 domain (Figure 18).127  
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Figure 20. Selected long-range NOEs identified in 2D NMR analysis are shown as dotted lines for peptides 4 
and 9. Reprinted with permission from George, K. L.; Horne, W. S. Heterogeneous-Backbone Foldamer 
Mimics of Zinc Finger Tertiary Structure. J. Am. Chem. Soc. 2017, 139, 7931-7938. Copyright 2017 American 
Chemical Society 
 
 
2.4 PROTEOLYTIC DEGRADATION  
The classical medicinal goal of peptidomimetic design was aimed toward drug 
development.145 High levels of enzymatic degradation in systemic circulation can lead to such low 
half-life times that delivery of material to the target tissue is quantitatively insufficient. Many 
strategies have been developed to fortify the proteolytic stability of native sequences including 
cyclization, L- residue to D- residue replacement, amidation or acetylation of either the N- or C-
terminus, and PEGylation.146 Additionally, a systematic comparison of proteolytic protection 
incurred by selected unnatural residues has also been reported for the enzyme chymotrypsin.108  
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In an interest to determine the extent of proteolytic protection imbedded in the backbone 
modifications of peptide 4 and 9, each was subjected to Trypsin digests alongside the native 
sequence in the presence of zinc. Trypsin cleaves at the C-terminal end of lysine and arginine 
residues. 
Results of the trypsin digest indicate each of the three peptide variants of Sp1-3 have very 
short half lives in the range of only minutes (Figure 21). Interactions between Tris buffer and zinc 
may have sequestered the metal to such an extent that the peptide was left in an unbound, unfolded 
state which would be highly susceptible to degradation. To test this, digests were repeated in 
HEPES buffer with an increased concentration of zinc.  
 
 
 
Figure 21. Trypsin digest of each peptide sequence with 1 M Trypsin, 50 M peptide, 1.3 eq ZnSO4, 
500 M TCEP and 50 mM Tris at pH 7. Each digest was run in triplicate. 
 
With the concentration of both peptide and trypsin remaining equivalent to the previous 
digests in TrisHCl, dramatically difference results were seen in HEPES buffer (Figure 22). At one-
hour, each of the peptides remains undigested. The lower metal binding propensity of HEPES 
coupled with an increase in zinc concentration from 1.3 to 3.6 equivalents likely enabled each of 
the peptides to bind metal and form a stable tertiary structure. While satisfying to see the increase 
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in proteolytic stability, these results do not indicate the extent to which the backbone modifications 
impact proteolytic degradation. Future steps to better understand this relationship would include a 
digest at higher concentrations of Trypsin. Additionally, digests could be run to examine the 
impact of a wider array of proteases such as the more promiscuous protease K and the relatively 
selective chymotrypsin.  
 
Figure 22. Trypsin digest of each peptide sequence with 1 M Trypsin, 50 M peptide, 3.6 eq ZnSO4, 
500 M TCEP and 50 mM HEPES at pH 7. Each digest was run in triplicate. 
   
 
2.5 CONCLUSIONS  
In summary, we have demonstrated here that the systematic backbone alteration of a 
ubiquitous metal-binding tertiary structure — the zinc finger domain Sp1-3 — can lead to 
heterogeneous-backbone mimics with native-like tertiary folded structures and metal binding 
environments along with superior folded stability. These findings are significant in the 
demonstration that a natural sequence of amino acid side chains can fold more effectively on a 
~20% unnatural backbone than on the natural all-α-peptide backbone on which that sequence 
evolved. The successful mimicry of a new tertiary structure class through sequence-guided 
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backbone alteration broadens the scope of this approach and suggests it is capable of recreating a 
wide array of natural folding motifs. The reported results on the Sp1-3 system also highlight the 
challenges and limitations of applying the method to complex folds through the extreme sensitivity 
of the metal-binding β-turn to alteration. Continued application to new prototype tertiary structures 
will lead to a greater understanding of the role of backbone chemical connectivity in protein 
folding and refinement of state-of-the-art design principles.  
 
 
 
 
 
2.6 METHODS 
Peptide Synthesis and Purification. All peptides were prepared by microwave-assisted Fmoc 
solid-phase synthesis on NovaPEG Rink Amide Resin. Microwave couplings were performed at 
70 °C for 4 min with N-α-Fmoc-protected amino acid (6 equiv), HCTU (6 equiv), DIEA (10 equiv) 
in NMP unless otherwise specified. Coupling reactions of Fmoc-Cys(Trt)-OH, Fmoc-His(Trt)-
OH, and Fmoc-Arg(Pbf)-OH were performed at room temperature for 30 min. Coupling reactions 
to N-Me-α-residues were performed in the microwave with 6 equiv PyAOP in place of HCTU. 
The pseudoproline dipeptide Fmoc-Leu-Ser-OH (Bachem) was utilized at Leu17Ser18 in each 
sequence and was coupled with PyAOP (6 equiv) and DIEA (10 equiv) in NMP at room 
temperature for 1 h. Fmoc deprotections were performed with 20% v/v 4-methylpiperidine in DMF 
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at 80 °C for 2 min. Resin was washed 3 x 1 min with DMF after each coupling and deprotection 
step. Cleavage from resin was achieved by treatment with a solution of TFA/EDT/H2O/TIS 
(94:2.5:2.5:1 by volume) over a period of 3 h followed by precipitation in cold ethyl ether. Pellets 
were collected via centrifugation and dissolved in solutions of 0.1% TFA in water and acetonitrile. 
Crude peptide was purified by preparative HPLC on C18 columns (100 Å pore size, 10 μm particle 
size  using gradients between water and acetonitrile with 0.1% TFA. The identity of each peptide 
was confirmed by MALDI-TOF MS and the purity of each assessed by analytical HPLC (Figure 
23, Table 1).  
Preparation and Storage of Stock Solutions. Peptides were stored as lyophilized powders under 
high vacuum. Peptide stock solutions were prepared fresh prior to each measurement. Metal stock 
solutions were stored at room temperature for a maximum of 3 weeks. Solvents used for sample 
preparation were purged by freeze-pump-thaw cycles and/or argon bubbling. The absence of 
rigorous efforts to exclude oxygen in solution preparation and manipulation led to rapid peptide 
oxidation on a time scale that varied depending on sequence, pH and temperature in the range of 
minutes to hours. Concentration of peptide solutions used in biophysical experiments were 
quantified by DTNB assay (aka Ellman’s assay) according to the procedure given by Thermo 
Scientific.147 Cobalt and zinc stock solution concentrations were determined either by ICP-AES, 
ICP-MS, or spectrophometrically with Zincon monosodium salt according to published 
methods.148  
UV-vis Spectroscopy. UV-vis spectra were acquired at 20 °C on a Cary 5000 Spectrophotometer 
in a 1 cm path length cuvette. Solutions contained 100 μM peptide, 20 mM HEPES (pH 7.0), 1.8 
mM TCEP with 1.3 equivalents of Co2+ (2 equiv Co2+ for peptide 5). Analytical HPLC prior to 
and post each experiment confirmed peptide was fully reduced. 
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UV-vis Titrations. CoCl2 (1700 μM) was titrated into a 100 μl solution of 100 μM peptide, 20 
mM HEPES (pH 7.0) with 1.8 mM TCEP in a 1 cm path length cuvette. Titrations were monitored 
at 20 °C on an HP Diode Array Spectrophotometer. Full spectra (200 - 800 nm) were recorded 
after each addition, following a 1 min equilibration. Spectra were corrected for dilution. Three 
replicate titrations were performed for each peptide. Analytical HPLC prior to and post each 
experiment confirmed peptide remained fully reduced. UV absorbance at 620 nm was plotted as a 
function of metal concentration and data were analyzed with Dynafit149 (system input: P + M <--
> MP; P + P + M <--> MP2). The extinction coefficients of the two complexes and dissociation 
constants for their formation were allowed to float in the fit. The total concentration of metal and 
peptide were held constant based on experimental parameters. Uncertainties for the values are 
listed as the standard error output from the fits. 
Isothermal Titration Calorimetry (ITC). ITC measurements were performed at 25 °C with a 
Malvern MicroCal iTC200. All solutions were purged with argon and adjusted to pH 7.4 ± 0.05 
prior to titration. At the onset of the experiment, 300 μL of a solution containing 100 μM peptide, 
50 mM HEPES, 100 mM NaCl was added to the cell. The syringe was filled with a solution of 
ZnCl2 (0.9 - 1.6 mM) in 50 mM HEPES, 100 mM NaCl. Typical experiments consisted of 2 μL 
additions per injection with a total of 20 injections in an anaerobic environment. Equilibrium was 
reached between each injection. Data were analyzed using software supplied with the instrument. 
Heats of zinc, peptide and buffer dilution were each measured from corresponding control 
titrations and subtracted from the experimental data prior to fitting.   
NMR Spectroscopy. For 2D NMR experiments, samples were prepared with 1.25 – 2.56 mM 
peptide, 1.3 equiv ZnCl2, and 0.2 mM DSS in 9:1 H2O:D2O at pH 7.0 (uncorrected). Spectra were 
recorded at 4 °C on a Bruker Avance-700 spectrometer. 512 t1-increments of 2048 points were 
 46 
acquired for COSY, TOCSY and NOESY, with mixing times of 80 ms for the TOCSY and 400 
ms for the NOESY. The free induction decay in both dimensions were multiplied by a phase-
shifted sine bell apodization function, zero filled, and Fourier-transformed to yield 4096 by 4096 
matrices. All spectra were processed using Topspin and referenced to internal DSS. Random coil 
chemical shift values used to generate the plots in Figure 7 were calculated for peptide 1 using the 
Poulsen IDP/IUP Random Coil Chemical Shift Server 
[https://spin.niddk.nih.gov/bax/nmrserver/Poulsen_rc_CS/], which implements published 
methods.150-152 
NMR Structure Calculations. Structure determination was carried out by simulated annealing 
using the Crystallography and NMR System software suite (CNS v1.3)153,154 and based on 
published methods previously applied to isolated zinc finger domains.127,155,156 For peptide 4, 234 
unique unambiguous inter-residue cross-peaks in the NOESY spectrum were assigned, integrated, 
and converted to interatomic distances based on calibration to i→i+1 HN-HN correlations observed 
in the α-helix (set as 2.8 Å).127 The resulting NOE-derived distances were sorted and 
conservatively classified as strong (≤2.7 Å), medium (≤3.5 Å), weak (≤4.5 Å), or very weak (≤5.5 
Å). Topology and parameter files for the N-Me-α-, β3-, and norleucine residues were manually 
prepared and included along with the implicit solvent force field for NMR structure determination 
included in CNS (protein-allhdg5-4). Simulated annealing was performed with 1000 steps of high-
temperature dynamics, followed by a 2000-step slow-cooling in torsional space, a 6000-step 
cooling cycle in Cartesian space, and a final 200-step minimization. The NOE energy term scale 
factor was set to 150 during heating and the first cooling cycle and 75 for the Cartesian cooling 
and final minimization. Other parameters were kept as their default values. Initially, 100 trial 
structures were generated using just the NOE distance restraints. The resulting ensemble showed 
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evidence supporting a secondary structure distribution, overall tertiary folding topology, and 
metal-binding site matching the published native Sp1-3 structure.127 Thus, additional restraints 
were prepared corresponding to hydrogen-bonds in the helix (residue range determined by short-
range NOE correlations) and tetrahedral coordination of Zn2+ by Cys4, Cys7, His20, and His24 (2.3 
Å for Sγ-Zn, 2.0 Å for Nε-Zn).157 200 trial structures were generated by simulated annealing using 
NOE distances along with the above additional restraints. The resulting set of models was filtered 
for NOE violations > 0.5 Å, resulting in the 9 structures presented as the NMR ensemble. Ensemble 
coordinates and additional experimental data are deposited in the PDB under accession code 5US3. 
Proteolysis Reactions Concentrations of active Trypsin were quantified by UV-vis spectroscopy 
with the substrate Nα-Benzoyl-L-arginine ethyl ester (BAEE). Reactions were each quenched with 
0.5% TFA and analyzed with analytical RP-HPLC. Integration of the resulting chromatogram was 
then plotted against total reaction time. 
 
 
 
 
 
 
 
 
Table 3. MALDI-TOF MS data for peptides 1-9 
# [M+H]+ m/z (average)  
 Calculated Observed 
1 3412.0 3411.7 
2 3405.9 3405.0 
3 3393.9 3392.4 
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4 3477.9 3478.7 
5 3365.7 3364.6 
6 3348.7 3351.0 
7 3477.9 3476.3 
8 3465.9 3465.1 
9 3363.8 3363.5 
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Figure 23. Analytical HPLC chromatograms of purified peptides 1-9. 
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Table 4. Backbone HN and Hα chemical shifts (ppm) for peptide 1, 4 and 9 
1 4 9 
  Hα HN   Hα HN   Hα HN 
K -a -a K -a -a K -a -a 
Y 4.662 8.845 Y 5.153 9.013 Y 5.166 8.981 
A 4.707 8.893 NMeA 5.426 -
b NMeA 5.473 -b 
C 4.824 8.653 C 4.871 8.647 C 4.856 8.642 
P 4.654 -b P 4.605 -b P 4.597 -b 
E 4.469 9.649 E 4.457 9.683 E 4.503 9.697 
C 5.129 8.166 C 5.174 8.195 C 5.157 8.145 
P 4.62 -b P 4.702 -b P 4.697 -b 
K 3.893 8.391 K 4.419 8.335 K 4.415 8.321 
R 4.985 7.883 NMeR 5.661 -b NMeR 5.677 -b 
F 4.902 8.55 F 4.733 8.719 F 4.738 8.703 
M 4.796 7.376 Nle 4.345 -
a Nle 4.501 8.489 
R -a -a R 4.952 7.852 R 4.935 7.803 
S 3.314 8.205 S 3.541 8.608 S 3.584 8.685 
D 4.38 7.237 D 4.654 8.451 D 4.647 8.45 
H 4.371 7.241 H 4.351 7.14 H 4.341 8.448 
L 3.372 7.179 L 3.184 7.686 L 3.231 7.795 
S 4.049 8.28 S 3.996 7.948 S 4.023 7.989 
K 3.995 7.547 K 4.107 7.605 K 4.137 7.724 
H 4.319 7.609 H 4.215 8.181 H 4.155 8.061 
I 3.646 9.038 I 3.431 8.983 I 3.45 9.599 
K 4.069 7.023 K 3.992 6.904 Aib -
b 7.223 
T 4.146 7.782 T 3.913 7.57 T 4.057 7.806 
H 4.686 7.279 H 4.781 7.778 H 4.505 7.733 
Q 4.797 8.957 Q 4.242 7.498 Aib -
b 7.511 
N 4.683 6.983 N 4.61 8.52 N 4.561 8.455 
K -a -a K 4.321 8.473 K 4.309 8.277 
K -a -a K 4.255 8.436 K 4.268 8.393 
a Resonance unable to be assigned unambiguously. b Atom does not exist. 
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3.0  PROGRESS TOWARD MIMICRY OF A MULTI- DOMAIN ZINC FINGER 
PROTEIN  
Work in the preceding chapter described the mimicry of the tertiary fold of a metalloprotein 
with heterogeneous-backbone variants that retained metal binding environments and dissociation 
constants indistinguishable from those of the native sequence. As prior precedents in 
heterogeneous-backbone modifications were limited for tertiary structures and absent in metal-
binding tertiary structures, this work advances the heterogeneous foldamer field. Remarkably, 
these backbone-modified designs also display increased thermodynamic fold stability relative to 
the native domain. This demonstrates that systematically placed backbone alterations can produce 
protein variants with characteristics superior to the native backbone. I was motivated to continue 
pushing the boundaries of complexity and apply the lessons learned in the single-domain zinc 
finger mimics to a larger and more intricate system: a multi-domain zinc finger protein and its 
interaction with DNA.  
The design and construction of peptide and protein mimics capable of defined interactions 
with biomacromolecular targets is an area of intensive research with a multitude of validated 
approaches. For example, many agents with structures reminiscent of secondary and tertiary motifs 
have been designed as modulators of protein-protein interactions (PPIs).113,158 Similar approaches 
have been applied to the develop peptides with antimicrobial activity and as actors in specific 
disease related signally pathways.17,159,160 Examples of this include designed  peptides with 
potent agonist activity for GPCRs such as the parathyroid hormone receptor and GLP-1R.161,162  
Challenges and opportunities inherent in targeting a multi-domain zinc finger protein 
include 1) expanding beyond mimicking structure to mimicking biological recognition of a 
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consensus DNA sequence, 2) extending the size of proteins able to be targeted by heterogenous 
backbone sequence designs, and 3) probing the generality of the designs successful in a single 
finger domain in a more complex context. Further, testing the heterogeneous backbone design 
principals in a prototype of increased complexity also opens the possibility to better understand 
optimal strategies for the design of such agents.  
From a practical standpoint, the goal of protein functional mimicry inherent in recreating 
the complex biological recognition of a consensus DNA sequence by an artificial agent would take 
the field of heterogeneous backbone designs one step closer to the long-term goal of real-world 
biomedical applications. Each increase in target complexity that can be met with a native-like 
folded mimic increases the possible sequences and structures for which backbone alterations could 
be applied expanding the scope of possible applications in such agents. Yet, as the complexity of 
the target fold or function increases, so too does the likelihood that a seemingly minor alteration 
will result in unintended consequences that potentially abolish or alter the fold or biological 
function (i.e. binding). Likewise, the more complex a prototype becomes the more opportunity we 
have to better understand the multitude of interactions which contribute to protein folding/binding 
and have been fine tuned in nature. Much like the lessons learned in prior work developing 
strategies for tertiary structure mimicry based on data accumulated related to secondary structure 
mimics, insights into the structural and thermodynamic consequences of ZF-ZF interactions and 
ZF-DNA interactions can be gained from both backbone designs that work as we envision as well 
those detrimental to function.  
An additional challenge presented by the attempt to mimic a multi-domain zinc finger 
protein is the size of the target.  The ~ 90 residue length was far larger than the 30 - 60 residues 
typical of artificial backbone sequences synthesized by solid-phase peptide synthesis (SPPS), 
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which had been the workhorse of the group up to this point. This increased length necessitated a 
different synthetic approach.  
3.1 METHODS FOR PROTEIN CHEMICAL SYNTHESIS 
The total synthesis of peptide and protein sequences of arbitrary size has long been 
considered a ‘grand challenge’ of synthetic organic chemistry. Emil Fischer referenced this in his 
Nobel Prize address in 1902:  
“Nevertheless, the chemical enigma of Life will not be solved until organic 
chemistry has mastered another, even more difficult subject, the proteins, in the same way 
as it has mastered the carbohydrates.”  
The challenge posed by peptide and protein synthesis, both at the turn of last century as 
well as at the turn of this century, has been continually met with marked progress and intense 
interest. Particularly dramatic strides resulted from protecting groups and coupling reagents 
becoming more widely available in the 1950’s and 1960’s and when Merrifield published his 
protocol for SPPS.163 Iterative optimizations of these protocols over the next decades led to 
improvements in efficiency; however the length of chains accessible remained limited to ~40 
residues. Various ligation chemistries to enable the synthesis of longer sequences did become more 
widely available by the late 1980’s, yet it was not until 1994 that the particularly sought-after 
characteristic of forming a native peptide bond was enabled.164-166 This ability to generate a native 
amide bond at the ligation site, along with its chemoselectivity, mild, aqueous environment and a 
lack of additional protecting groups quickly drove native chemical ligation (NCL) to the forefront 
of protein synthesis methodology.167 
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NCL involves the reaction between two peptide fragments: one with a C-terminal thioester, 
the other with a N-terminal cysteine. Mechanistically, NCL proceeds via a thiol-thioester exchange 
through transthioesterification that generates a thioester-linked intermediate. A subsequent S→N 
acyl transfer then produces a stable native peptide bond (Figure 24). This reaction proceeds at near 
neutral pH in phosphate buffer with a chaotropic agent, such as guanidine, to aid in peptide 
dissolution and tris(2-carboxyethyl)phosphine (TCEP) to minimize oxidation of unprotected 
cysteines.   
 
Figure 24. Scheme detailing the mechanism behind native chemical ligation. 
A variant of NCL is expressed protein ligation, in which a chemically synthesized peptide 
is chemoselctively and regioselectively ligated to a recombinant protein.168 In the context of our 
heterogenous backbone design work, expressed protein ligation opens the doors to introduce 
backbone-altered residues as necessary via SPPS in one segment while subsequently ligating this 
to a second segment, which contains all  residues and is produced through expression.  
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As discussed above, two fragments are necessary for NCL or expressed protein ligation: 
one bearing an N-terminal thiol and the other displaying a C-terminal thioester. Historically, C-
terminal thioesters were prepared as derivatives of alkyl thioesters by in-situ neutralization driving 
Boc-SPPS. However, nearly half (43%) of the published ligations carried out since Kent’s 1994 
publication have made use of thioesters generated by Fmoc methods via either N-
acylbenzimidazolinone (Nbz, 13%) or hydrazide169 (30%) (Figure 25).170 Each of these methods 
rely on a C-terminal functional moiety conveniently stable to Fmoc-SPPS conditions and readily 
able to convert to a thioester by a specific chemical reaction, while still attached to the resin in the 
case of Nbz or post cleavage in the case of hydrazide.  
 
 
Figure 25. Structures of common thioester precursors prepared via hydrazide and N-acylbenzimidazolinone. 
3.1.1 Zif268  
Zif268 is a three finger, multidomain Cys2His2 zinc finger protein that regulates eukaryotic 
gene expression via recognition of specific DNA sequences, much like the Sp1 system in which 
the single domain studies from the previous chapter were carried out. Each finger adopts a  
tertiary fold upon metal coordination and is stabilized by a conserved hydrophobic core. The 
crystal structure of Zif268 bound to a consensus DNA sequence is shown in Figure 26 with each 
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of the fingers extending along the major groove and primary base contacts residing along the 
exterior edge of each N-terminal helix.  
 
Figure 26. Zif268 bound to the consensus DNA sequence with a zoom of the finger 1 turn. (PDB: 1AAY) 
 
Crucially, the first finger of Zif268 (Zif268-1) contains an extended ‘irregular’ type I CX4C 
turn rather than the CX2C turn in the Sp1-3 sequence (Figure 27). Given that each of the turn mimics 
applied in the single domain Sp1-3 prevented the formation of the  tertiary structure, the CX4C 
turn in Zif268-1 presents an opportunity to examine the same turn alterations in a second structural 
context with a similar  tertiary fold.  
 
Figure 27. Comparison of native sequence turns in Sp1-3 and Zif268-1. 
Probing these turn alterations in Zif268-1 aids in determining if the lack of folding seen in 
turn variants of Sp1-3 can be correlated to the smaller (CX2C) and more complex ‘double turn’ of 
F2 F3F1
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the Sp1-3 system specifically or if there is an additional aspect of the  zinc finger structure 
that has yet eluded us. It was our hope that the additional two residues buttressing the metal binding 
cysteines would allow sufficient space to ensure turn modifications do not perturb the precise 
tetrahedral coordination of metal by neighboring cysteines. The notion that the extended turn might 
allow for additional turn alterations is supported by work done by Thornton in which the CX4C 
turn of zinc finger YY1-3 was successfully modified with a bicyclic beta turn mimetic.171  
Previous work published toward total synthesis of Zif268 includes two approaches. In 
1999, Dawson et al. demonstrated the utility of his recently published native chemical ligation 
methodology by ligating together three chemically prepared (via Boc SPPS) fragments of Zif268 
at two Xaa-Cys ligation sites with thioesters derived from a trityl-associated mercaptopropionic 
acid-leucine (TAMPL) resin.172 In later work, Fehr et al. took a semi-synthetic approach toward 
Zif268 with expressed protein ligation in which a chemically synthesized finger three of Zif268 
was ligated to an expressed segment containing Zif268(1-64).173 In each of these cases, the DNA 
binding capabilities of the final Zif268 product were assessed via CD spectroscopy and showed 
that both synthetically accessed Zif268 sequence did bind native DNA. 
3.1.2 Design of a Synthetic Route to Heterogeneous-Backbone Zif268 Mimics 
As Xaa-Cys ligations lack the need for any post ligation synthesis manipulations, the 
optimal potential ligation sites in the Zif268 sequence are: Gln35-Cys36, Ile38-Cys39, Ala63-Cys64 
and Ile66-Cys67. Given the known incompatibility of the hydrazine moiety with a C-terminal 
glutamine residue (due to an intramolecular cyclization that occurs between the hydrazide and the 
glutamine side-chain during SPPS)169, along with the slow reaction time for beta branched residues 
such as isoleucine, the use of Nbz as the acyl donor for the Zif268 enables two more easily 
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obtainable ligation sites (Gln-Cys and Ala-Cys). Of note, the acyl hydrazide strategy would also 
be feasible at the Ala-Cys site.  
Summarizing the proposed route to form the C-terminal thioester from an aminoanilide 
moitety, the Dbz residue is coupled to the resin prior to SPPS extension of the peptide sequence. 
After synthesis of the desired segment is complete, the entire resin-bound peptide is subjected to 
p-nitro- phenylchloroformate which, along with the subsequent basic conditions, results in a cyclic 
C-terminal N-acyl urea. The N-terminus of the peptide chain protected via a Boc group during this 
cyclization.  Following cleavage from the resin and simultaneous Boc deprotection, the peptide-
Nbz (N-acyl-benzimidazolinone) undergoes thiolysis to yield a thioester that is then available for 
ligation with a free thiol (Figure 28).  
 
 
Figure 28. Generic scheme for activation and cyclization of Dbz residue followed by ligation. 
 
While an N-terminal thiol is straightforward to generate via SPPS, in the context of 
expressed protein ligation additional considerations must be taken into account due to fact that the 
start codon for translation also codes for methionine. One method to produce a peptide segment 
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with an N-terminal thiol via expression takes advantage of the protease thrombin. This protease 
recognizes the consensus sequence LVPR|GS as well as similar sequences with a cysteine in place 
of the glycine. A sequence similar to this consensus sequence can be placed N-terminal to the 
cysteine that is intended to be ligated in NCL, thereby mimicking the consensus sequence. 
Incubation with thrombin, post expression, can effectively produce an N-terminal thiol (Figure 
29). 
 
Figure 29. Scheme depicting protocol of post expression procedures to acquire the target sequence with an N-
terminal cysteine. 
3.2 HETEROGENEOUS BACKBONE VARIANTS OF ZIF268 
Designs of heterogeneous-backbone variants of Zif268 focused on altering the backbone 
of the first finger while leaving the backbone along the second and third fingers undisturbed. 
Reminiscent of the Sp1-3 designs, two cross-strand N-methyl residues were placed along the  
strand and four 3-residues were placed along the exterior of the helix. Designing these alterations 
based on results from Sp1-3 allows us to test the hypothesis that the strategies for backbone 
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modification would be generally applicable. Four variants were designed with turn modifications 
Glu9 and Ser10 of the prototype sequence, D-ProGly, AibGly and Ornithine (Error! Reference 
source not found.). Each of the above alterations were placed with consideration of minimizing 
possible impacts related to 1) single domain folding, 2) ZF-ZF interactions and 3) ZF-DNA 
interactions.  
 
 
Figure 30. Sequence of multi-domain Zif268 along with backbone variants of finger 1. 
While one of the overarching goals of designing backbone alterations for a multi-domain 
zinc finger remained focused on measuring the differences between backbone altered variant-DNA 
interactions and native sequence-DNA interactions, the first step along this path was to ensure that 
the backbone alterations placed in the first finger (Zif268-1) continued to support the native 
tetrahedral metal coordination environment as well as the  tertiary fold seen in natural Zif268-
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1. Along with this, examining the backbone design principles in the context of a second zinc finger 
further demonstrates the generality of these principles.  
Native and backbone modified E1-K32 residues of finger one were synthesized and a 
primary UV-vis spectroscopy assay was carried out in the presence of excess Co+2 in 20 mM 
HEPES at pH 7.0 with ~ 100 μM peptide. The peptide samples used for each of these assays were 
not entirely pure according to MS analysis. Each sample contained varying degrees of single 
residue deletion sequences as well as other SPPS byproducts (vida infra). Never the less, the assay 
results are informative. The shape, intensity and position of diagnostic bands in the 500-700 nm 
region suggest the tetrahedral coordination of Co+2 for variants 10, 11, 12 and 13 (Figure 31) and 
provide compelling evidence for a native-like  tertiary fold in the context of the first finger. 
 
Figure 31. Absorption spectra with saturating concentrations of CoCl2.   
 
While confirmation with pure samples would be needed for any definitive conclusions, 
data supporting the fold of variant F1 (11) in which lessons from backbone alterations in the Sp1-
3 context were applied to Zif268-1, suggests significant generality of design principals for 
backbone alterations developed in the Sp1-3 system. In addition, UV-vis spectroscopy data 
indicating the tetrahedral coordination of cobalt by variants F1 (12) and F1 (13) supports that both 
D-ProGly and AibGly turn modifications are tolerated in the  fold of Zif268-1. This is in direct 
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contrast to what was seen in turn-modified Sp1-3 variants, which lacked the propensity to bind 
cobalt. It is possible that the additional two residues spanning the CX4C turn of Zif268-1 create 
enough distance to ensure the turn modifications do not perturb cysteine coordination. Likewise, 
it also possible that the mirror image type-I′ and II′ turn conformations promoted with the turn 
mimics are better tolerated in the irregular type I turn of Zif268-1 than in the double turn of Sp1-
3.  
3.3 BARRIERS MET IN ZIF268-1 SYNTHESIS 
Upon attempting to produce larger quantitates of the E1-K32 domain of Zif268-1 and the 
variants of Zif268-1, a number of barriers were encountered which prohibited synthesis of the 
necessary pure material to conduct UV-vis spectroscopy as well as additional analysis. While solid 
phase peptide synthesis (SPPS) is a well-studied procedure, it remains a time consuming and non-
trivial aspect of studying heterogeneous backbone designs. Below, I survey key technical obstacles 
encountered in the synthesis of Zif268-1 along with efforts to overcome these issues.  
One barrier met during the pursuit of additional Zif268-1 material was the co-elution of 
single-residue deletion products with desired material upon HPLC purification. In Figure 32a 
overlapping peaks in the HPLC trace can be seen; Figure 32b serves as a comparison in which one 
main peak can easily be isolated. The cause of single-residue deletions that coelute with the desired 
product appears to originate from difficult couplings to Cys and to Pro. The former is due to the 
steric hindrance of the trityl (Trt) side-chain protecting group and the latter, the decreased 
nucleophilicity of proline’s secondary amine. Both these factors decrease the efficiency of 
coupling, which in turn increases the possibility that a percentage of the growing peptide chain 
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will not complete a coupling reaction. As the chain continues to grow with additional amino acid 
acylations the resulting sequence, which lacks complete residue coverage, can at times co-elute 
along with the desired sequence during HPLC purification. When coelution occurs, the inability 
to isolate the desired sequence in high purity prevents further biophysical analysis. Once an 
incomplete coupling has been identified either through analytical techniques such as a MALDI of 
a small batch cleavage of the growing peptide chain or upon final purification steps, future 
syntheses can incorporate a second coupling reaction at the challenging site as well as a capping 
reaction to intentionally terminate free amines for which two couplings reactions were insufficient 
for acylation. Both of these approaches, when applied to each difficult coupling, were successful 
in ensuring challenging couplings went to completion and chains that did not complete the 
coupling reaction did not coelute upon HPLC purification.  
 
 
Figure 32. HPLC traces comparing the overlapping elution of peaks (A) to a single peaks able to be 
isolated with high purity (B).  
 
An additional barrier encountered was the production of a significant byproduct attributed 
N to O acyl migration during the TFA cleavage of peptide from resin. HPLC traces of a synthesis 
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in which an N to O acyl migration occurred can be seen in Figure 33 as a shoulder along with a 
second shoulder due to a single residue deletion. The proposed mechanism of this side reaction is 
shown in Figure 35.  Acyl shifts can occur at serines or threonines in Fmoc based SPPS; the 
likelihood of occurrence is dependent on the specific peptide sequence.174 In the presence of typical 
-residues, the hydroxyl side chain of threonine may attack the carbonyl of the previous N-
terminal residue cleaving the peptide chain at the amide bond between Thr and the residue N-
terminal to Thr. This cyclization step is reversible and the conversion back to the native backbone 
is far faster than the cleavage pathway. In the context of heterogeneous backbones, the extended 
backbone of a 3-threonine introduces an additional irreversible path leading towards N to O acyl 
shifts in which the hydroxyl side chain of threonine may be prone to attack the intraresidue 
carbonyl. Due to the additional carbon along the backbone, this forms a five membered lactone 
and results in cleaving all residues C-terminal to the 3-threonine. The resulting section of the 
desired peptide can be identified via MALDI. To reduce the occurrence of N to O acyl shifts in 
Zif268-1, a native -threonine was returned to the sequence in place of the  threonine. Upon re-
synthesis with the native -threonine in this position, chain fragmentations due to N to O acyl 
shifts were not indicated in the mass spectrometry analysis.  
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Figure 33. HPLC trace showing two shoulders adjacent to the main peak. Upon MALDI ionization, molecular 
weights indicated one shoulder was due to an N to O acyl migration, whereas the other shoulder is due to a 
single residue deletion. 
 
Despite resolving issues with both single residue deletions and N to O acyl shifts, an 
additional barrier in the synthesis of Zif268-1 remained problematic: base catalyzed aspartimide 
formation. This side reaction is known to occur during Fmoc deprotection and can be identified by 
an -18 mass (present in MALDI analysis, Figure 34).175 The reaction occurs through the 
nucleophilic attack of the aspartic acid side chain by the nitrogen atom attached to the carbonyl 
(Figure 35). This results in an apartimide ring that is then vulnerable to a nucleophilic attack of the 
imide ring by piperidine. In the each of the Zif268-1 sequences the initial aspartimide ring was 
indicated by mass spectrometry; however no additional piperidine attack was observed.  A known 
solution to aspartimide formation is to reduce the basicity of the deprotection solution. This 
minimizes the likelihood that piperidine will deprotonate the backbone amide nitrogen, which 
decreases the likelihood for attack of the side chain ester. 0.1 M 1-hydroxybenzotriazole (HOBt) 
can be added to the Fmoc deprotection solution to this end.175 In the case of the Zif268-1 variant 
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containing the D-ProGly turn (12), the addition of HOBt to the deprotection solution was met with 
success in minimizing the aspartimide formation observed during formation. However, 
aspartimide formation remained problematic in the wild-type Zif268-1 sequence even in the 
presence of HOBt. 
 
 
Figure 34. MALDI-MS data showing target sequence along with -18 and -36 masses.  
 
Several alternative pathways for future mitigation of aspartimine formation in the Zif268-
1 wild-type sequence exist. Purchasing fresh HOBt is one example. HOBt is light sensitive and 
the material used in the previous reactions was multiple years old. Additionally, ethyl 2-cyano-2-
(hydroxyimino)- acetate (Oxyma) has also been shown to reduce aspartimine formation; Oxyma 
also has the added benefit of lacking the explosive potential of HOBt.176,177 The addition of 5% 
v/v formic acid to the deprotection solution has also been shown to mitigate aspartimide 
formation.177 Alternatively, aspartic acid with sterically demanding protecting groups such as 3-
methylpent-3-yl (OMpe)178 and β-2,3,4-trimethyl-pent-3-yl179 can also be utilized. Future 
synthesis of the wild-type Zif268-1 sequence could incorporate one or several of these pathways 
to mitigate aspartimide formation. 
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Figure 35. Mechanisms and structures for select barriers in SPPS a) Aspartimine formation b) potential 
pathways for N to O acyl migrations in both  and  backbones c) Structures underlying the steric hindrance 
of the trityl protecting group and the secondary amine of proline; each of which can lead to decreased coupling 
capacity and single residue deletions. 
 
At this point, it was determined that an efficient synthesis of Zif268-1 necessitated 1) 
double coupling/capping after each cysteine and proline residue to prevent single residue deletions, 
2) a native -backbone threonine rather than  threonine at residue 29 to avoid N to O acyl shifts, 
3) 0.1 M HOBt in the deprotection solution to suppress aspartimide formation in sequences with 
D-Pro-Gly as the turn and 4) continued efforts to mitigate aspartimide formation in the wildtype 
Zif268 sequence.  
Steps 1 through 3 were each shown to minimize or eliminate the given barrier while several 
possible approaches to step four yet exist for optimization of native Zif268-1. Despite the strides 
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taken to determine these synthesis parameters, sufficient material was not produced in time to carry 
studies into the next steps, which were planned to focus directly on confirming the tertiary structure 
of both the backbone altered and  backbone Zif268-1 finger through 2D NMR experiments. 
Confirming the extent to which the structure of the first finger of Zif268 was altered or not altered 
would then lead to the next step: synthesizing the full 89 residue three-domain sequence with 
backbone alterations in the first finger with the overall aim of determining the effect of backbone 
alterations on DNA binding via circular dichroism (CD).  
3.4 MODULAR APPROACHES TO THE MULTI-DOMAIN SEQUENCE 
In parallel to efforts aimed at optimization of the synthesis of Zif268-1 and variants, we 
sought to establish a modular approach to the full three-finger Zif268 protein.  Through this work 
our goal was to expand the length of potential sequences amenable to heterogenous design 
principles and to determine how backbone alterations impact Zif268 - DNA binding in comparison 
to the wild type sequence. We pursued two courses: one based on total chemical synthesis through 
iterative NCL reactions and the other based on expressed protein ligation involving synthesized 
and bacterially produced fragments of the full length protein.  
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3.4.1 Approach A 
 
 
Figure 36. Schematic of “Approach A” which includes and expressed C-terminal segment combined with a 
chemically synthesized N-terminal segment, ligated together at one single site. 
 
The initial design toward the 88 residue Zif268 sequence, “Approach A”, aimed to utilize 
a single native chemical ligation site at the intersection of residues Q35 and C36. Fragment E1-Q35 
was to be synthesized through Fmoc-SPPS and on-resin generation of o-aminoaniline N-
acylurea (Dbz) moiety, enabling the formation of a thioester at the C terminal Q35 (Figure 36). 
Residues C36-K88 were to be produced via protein expression. We envisioned this modular 
approach would enable multiple backbone-modified variants to be synthesized and ligated in 
parallel to a single batch of expressed native C36-K88 thus creating an efficient path towards 
production of several multi-domain variant designs. While several ligations sites were possible, 
position Q35 - C36 was chosen due to the ease of ligating directly with a C-terminal cysteine 
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(eliminating the need for post synthesis desulfurization steps) and with an eye to minimize 
additional steps at the thioester. The sterically unencumbered C-terminal Gln should also give a 
faster reaction than would occur with beta branched residues such as Ile, Thr and Val.180  
 
Figure 37. pET vector design with histidines tag, cleavage site and C36-K88. 
 
A pET vector containing a histidine tag for nickel column purification along with a 
thrombin cleavage site and Zif268 residues C36 through K88 was designed and purchased in a 
stab culture of E. coli strain Stbl3 (Figure 37). Expression in BL21(DE3) E. coli and subsequent 
Ni column purification of this “His6-ThrombinCleavage-C36-K88” peptide sequence resulted in a 
large batch of protein necessitating little optimization apart from increasing the concentration of 
imidazole to outcompete with the zinc finger during nickel column purification. SDS-PAGE after 
initial expression and purification with a nickel column is shown in Figure 38 along with a second 
SDS-PAGE showing an optimized protocol for nickel column purification consisting of an 
imidazole gradient in place of static imidazole concentration. With the high affinity zinc fingers 
have for divalent metals, additional imidazole was advantageous to maximize elution of the target 
sequence. As is visible in B2, even after nine elution runs with a maximum of 0.8M imidazole, a 
great deal of the target sequence can be seen eluting in the tenth elution with 6M imidazole. Future 
nickel column purifications would benefit from increased gradients of imidazole due to the 
additional target sequence peptide still eluting in E10 elution (Figure 38 B2).  
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Figure 38. Two examples of SDS-PAGE run post expression of His6-Thombincleavage-C36-K88. A) A static 
concentration of 0.4M imidazole is used to elute target sequence from nickel column. B1 and B2) A 
concentration gradient of imidazole allows increasing amounts of the target sequence to elute from the nickel 
column. L=ladder, SN=supernatant, P=pellet, FT=flow through, W=wash, E# = elution with Imidazole. 
 
Elutions 1 through 9 were collected and analyzed with HPLC (Figure 39). One main peak 
can be seen eluting around 30% B. Attempts to confirm the molecule though MALDI-MS, were 
unsuccessful, as ionization proved challenging. Nonetheless, the appropriate MW observed in the 
gel match expectation for the construct. Thus, we proceeded to examine steps toward thrombin 
cleavage of the expression tag.  
 
Figure 39. Analytical HPLC trace of collected elutions 1 through 9 
 
0 5 10 15 20 25 30
150
200
250
300
Minutes
 72 
 In effort to determine optimal conditions for proteolytic cleavage of the expression tag, a 
large number of small-scale reactions were run with varied thrombin concentration, peptide 
concentration, temperature and reaction time. The final conditions found to be most successful 
were 10°C, 50 mM Tris HCl, pH 8, 100 mM NaCl, 5 mM CaCl2, 20 units thrombin per 1 mg 
peptide. Reactions were monitored via HPLC with the mass of both the uncleaved peptide and the 
histag/thrombin cleavage segment able to be identified via MALDI. It is likely that the large peak 
growing in at elution time 28 minutes in Figure 40 is the desired C36-K88 product yet no definitive 
confirmation through mass spectrometry could be made either by MALDI or by ESI.  
 
 
Figure 40. Analytical HPLC traces post Thrombin cleavage at designated time points. 
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Next steps to confirm the identity of the presumed desired product would include SDS-
PAGE to confirm the relative molecular weight of the presumed peak. Though given the 
similarities in weight, the starting material (MW = 7818 g/mol) and the target sequence (MW = 
6380 g/mol) may be difficult to differentiate through SDS-PAGE.  An additional test reaction 
between the presumed peak and a compound containing a thioester followed by HPLC purification 
would also aid in determining if an N-terminal cysteine is present in the peak eluting at 28 minutes. 
If no change in retention time is present then it is likely the peptide eluting at 28 minutes does not 
contain a free cysteine and therefore is not the desired C36-K88 product.  
3.4.2 Approach B 
Given the difficulties encountered with the thrombin cleavage in Approach A, an alterative 
strategy toward the multi domain zinc finger protein, “Approach B”, was designed. While 
expressed protein ligation was a fundamental aspect of Approach A, Approach B aimed to 
chemically synthesize three separate segments of the multi-domain zinc finger via SPPS and utilize 
NCL at two separate ligation sites: Q35/C36 and A63/C64 (Figure 41).  
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Figure 41. Schematic for “Approach B” in which three segments are chemically synthesized and ligated 
together at two ligation sties.  
 
Two peptide segments with C terminal thioesters were necessary for Approach B: one C-
terminal to Q35 and the other C-terminal to A63. Both thioesters necessary for NCL were formed 
via a Dbz residue at the C-terminus, much like what was done in Approach A. Rather than utilizing 
the Dbz residue to form the thioester, a modified Dbz residue was used: N-Me Dbz. The N-methyl 
group on the para-amino group of the residue significantly decreases the sensitivity for undesired 
acylation while retaining enough reactivity at the remaining amine to couple the following residue 
with HATU in anhydrous DMF.181 An additional optimization in synthesis toward a thioester-
bearing segment included a glycine spacer coupled to the resin prior to the dbz residue. This 
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glycine minimizes steric hindrance in the resin loading reaction. Upon ligation, the glycine is lost 
with the Dbz moiety as equilibration is reached with the added thioesters.   
To facilitate a one-pot sequential ligation, C36-A63-NMeDbz was prepared with an N-
terminal 1,3-thiazolidine-4-carboxo (Thz) protecting group.182,183 Following ligation with D65-K88, 
the free thiol should be easily unmasked with methoxyamine to enable the extension in the N-
terminal direction (Figure 42).  
 
 
Figure 42. Transformation of Thz to a free cysteine with methoxyamine 
 
Given the methods laid out above, Approach B was pushed forward with the synthesis and 
TFA cleavage of E1-Q35-Dbz-G on rink resin with Fmoc SPPS. Microcleavages at regular intervals 
during synthesis confirmed successful couplings up to F15. Further microcleavages after complete 
synthesis and before Dbz cyclization showed promising yet inconclusive masses in the region of 
the expected weight (Figure 43a). A subsequent analytical HPLC trace post-cyclization of Dbz 
resin also showed a promising main peak followed by a large amount of overlapping material 
(Figure 43a). Neither MALDI nor ESI mass spectrometry of the isolated peak resulted in ionization 
(Figure 42b). Thus identification of the final E1-Q35-Dbz-G was not confirmed. 
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A.  
B.   
 
 
Figure 43. A) Inconclusive MALDI data after complete synthesis of E1-Q35-Dbz-G .B)Analytical HPLC of 
E1-Q35-Dbz-G  
 
Next steps for progress in the complete synthesis of the three finger Zif268 include 
improved confirmation of E1-Q35-Dbz.   
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3.5 CONCLUSIONS 
Progress on several fronts suggested the synthesis of the multi-domain zinc finger foldamer 
was on the right track. Yet, unanticipated challenges, detailed above, limit us to a discussion of 
barriers remaining rather than of a decisive test of the hypothesis of multidomain zinc finger 
protein mimicry. The difficulty producing a multi-domain zinc finger through “Approach A” was 
primarily due to complications with confirming the identity of the target sequence after thrombin 
cleavage. The peak eluting at 28 minutes showed promise (Figure 40). Though, it would need to 
be confirmed through optimization of MS enabled methodology or a test reaction with a compound 
containing a thioester. Confirmation of the target sequence was also the limiting step for 
“Approach B”. In this case it was E1-Q35-Dbz that was potentially synthesized but unable to be 
confirmed.  
The preliminary spectroscopic data for Zif-268 finger 1 variants (Figure 31) do, however, 
suggest that our initial design principles for backbone alterations in Cys2His2 zinc fingers can be 
applied to a second native zinc finger sequence. This demonstrates the generality of the initial 
design principles. The tetrahedral coordination of metal by variants with backbone alterations in 
the turn region also further validates the design principals set out in Chapter 2, as these proved 
challenging in the first Sp1-3 sequence due to the tight turn. These variant’s ability to mimic the 
structure and binding of native Zif268-1 suggests that if Approach A or B of the total synthesis 
with backbone alterations in the first finger were to be complete, there is high potential that the 
three fingers would each fold into a native like tertiary structure. The DNA binding propensity 
could then be determined with a simple CD scan.  
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3.6 METHODS 
Peptide Synthesis and Purification All peptides were prepared using microwave-assisted Fmoc 
solid-phase peptide synthesis techniques on NovaPEG Rink Amide Resin. Microwave couplings 
were performed at 70 C for 4 minutes with N- -Fmoc-protected amino acids (6 eq), HCTU (6 
eq), DIEA (10 eq) in NMP for all amino acids except Fmoc-Cys(Trt)-OH, Fmoc-His(Trt)-OH and 
Fmoc-Arg(Pbf)-OH which were performed at room temperature. Residues coupled to N-Me were 
coupled with 6 eq PyAOP and 10 eq DIEA in NMP at 70 C for 4 minutes. The pseudoproline 
dipeptide Fmoc-Leu-Ser-OH was utilized to prevent aggregation at residues L17 and S18 and was 
coupled with PyAOP (6 eq), DIEA (10 eq) in NMP at room temperature for one hour (Figure 25). 
Fmoc deprotection was achieved with 20% 4-methylpiperidine in DMF at 80 C for 2 minutes. 
Resin was washed 3 x 1 minute with DMF after each coupling and deprotection step.  Figure 25. 
Structure and placement of LS pseudoproline dipeptide. Cleavage from resin was achieved with a 
solution of TFA/EDT/H2O/TIS (94:2.5:2.5:1) over a period of 3 hours followed by precipitation 
in cold ethyl ether. Pellets were collected via centrifugation and dissolved in solutions of 0.1% 
TFA in water and acetonitrile. Crude peptide was purified on C18 HPLC columns using 0.1% TFA 
with a gradient of acetonitrile. Purified peptides were identified with MALDI mass spectrometry.  
Preparation and Storage of Stock Solutions. Peptides were stored as lyophilized powders under 
vacuum to reduce contact with oxygen. Peptide stock solutions were prepared fresh prior to each 
measurement. Metal stock solutions were stored at room temperature for a maximum of 3 weeks. 
Solvents used for sample preparation were purged by freeze-pump-thaw cycles and/or argon 
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bubbling. The absence of rigorous efforts to exclude oxygen in solution preparation and 
manipulation led to rapid peptide oxidation on a time scale that varied depending on sequence, pH 
and temperature in the range of minutes to hours. Concentration of peptide solutions used in 
biophysical experiments were quantified by DTNB assay (aka Ellman’s assay) according to the 
procedure given by Thermo Scientific.147 Cobalt and zinc stock solution concentrations were 
determined either by ICP-AES, ICP-MS, or spectrophometrically with Zincon monosodium salt 
according to published methods.148  
Peptide Expression and Purification. The N-terminal 6xHis-tagged –Thrombin Cleavage-
Zif268 (C36-K88) expression construct was obtained from Cyagen Biosciences. The plasmid was 
transformed into E. Coli BL21 codon plus (DE3) competent cells (Invitrogen) using a pET vector. 
A single colony was picked up and grown overnight at 37 oC in 10 mL of Luria-Bertani (LB) broth 
in presence of 50 μg/mL ampicillin and 35 μg/mL chloramphenicol. The culture was diluted 100-
fold and allowed to grow at 37 oC to an optical density (OD600) of 0.8, and protein expression was 
induced overnight at 18 oC with 1 mM IPTG in an Innova 44® Incubator shaker (New Brunswick 
Scientific). Proteins were purified as follows: harvested cells were resuspended in 15 mL lysis 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, 10% glycerol, 25 mM 
imidazole, Lysozyme, DNase, and Roche protease inhibitor cocktail). The cells were lysed by 
pulsed sonication (Qsonica-Q700), and centrifuged at 13000 rpm for 40 min at 4 oC. The soluble 
extracts were subject to Ni-NTA agarose resin (Thermo) according to manufacturer’s instructions. 
After passing 20 volumes of washing buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM β-
mercaptoethanol, 10% glycerol, and 25 mM imidazole), proteins were eluted with a buffer 
containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, 10% glycerol, and 
400 – 800 mM imidazole. The protein concentration was determined using Bradford assay kit 
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(BioRad Laboratories) with BSA as a standard. The concentrated proteins were stored at -80 oC 
before use.  
UV-vis Spectroscopy. UV-vis spectra were acquired at 20 °C on an HP 8452A Diode Array 
Spectrophotometer in a 1 cm path length cuvette. Solutions contained 100 μM peptide, 20 mM 
HEPES (pH 7.0), 1.8 mM TCEP with 1.3 equivalents of Co2+. Analytical HPLC prior to and post 
each experiment confirmed peptide was fully reduced. 
Dbz Resin Loading.  Dawson Dbz NovaSynTGR resin was swelled in DCM for 60 minutes and 
washed with DMF. Fmoc deprotection was achieved with 20% 4-methylpiperidine in DMF at 
80 C for 2 minutes. A room temperature coupling was performed overnight with N- -Fmoc-
protected amino acids (6 eq), HATU (6 eq), DIEA (10 eq) in anhydrous DMF. Resin loading was 
measured via UV-vis with 4-methylpiperidine. An alternative procedure included coupling an N-
MeDbz linker to a rink amide resin preloaded with glycine. Coupling to the N-MeDbz linker was 
preformed overnight with N- -Fmoc-protected amino acids (6 eq), HATU (6 eq), DIEA (10 eq) 
in anhydrous DMF. SPPS proceeded as stated above. rThe final residue of C-terminal Dbz peptides 
was introduced as a Boc protected amino acid.  
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4.0  BROADER OUTLOOK 
The preceding discussion focuses on and contributes to the development of design 
principles for increasingly diverse peptide-like entities. Potential applications of such entities fall 
overwhelmingly in the therapeutic sphere. Below I provide a brief overview of the chemical space 
of current therapeutics as well as the potential for and barriers to market entry in the case of both 
native and backbone-modified peptides.  
Small molecules have dominated the therapeutic market for the past century.184,185 Their 
ideal characteristics of membrane permeability, metabolic stability, oral bioavailability and a 
relatively low production cost (in comparison to other types of drugs) have allowed for remarkable 
advances in medicine.184 Yet, small molecules can suffer from low target selectivity that results in 
a high off-target binding and manifests as side effects. Due to their small size, they also fall short 
when it comes to targets with large, flat and nonpolar surfaces – a class that is rapidly growing.186 
 Advances in recombinant protein expression, purification and characterization in the past 
30 years have gradually increased the viability of proteins as drugs and opened the door to 
harnessing their remarkable target selectivity and impressive ability to bind precisely the types of 
surfaces that had long eluded small molecules.187 Innovations in delivery systems have mitigated 
previous concerns related to delivery. Continued success in transciptomics, proteomics and 
genomic technologies has paved a path towards a greater emphasis on proteins as drug 
candidates.186,188 As of 2013, success rates of bringing a biologic to market was about twice that 
of a small molecule.187  
The two main established classes of successful drugs are then small molecules, defined by 
molecular weight of less than 500 g/mol, and biologics, defined by a molecular weight of over 
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5000 g/mol.189 A significant gap exists between these two classes. Likewise, a significant gap 
exists in the types of targets each of these are able to bind. It is estimated only 10% of proteins 
have pockets deep enough to be bound by small molecules. Further, only 10% of possible targets 
reside in the extracellular space accessible by biologics.190 This still leaves the vast majority of 
drug targets as potentially “undruggable” with current chemical classes.  
 Peptide therapeutics offer the potential to fill the gap in molecular weight between 
biologics and small molecules while also touting an impressive combination of attributes that align 
well with the increasing numbers of targets with large, shallow and nonpolar binding sites. Many 
protein-protein interfaces (PPI) can even now be classified as “druggable” due to the availability 
of increasing numbers of peptide-based drugs.191 In addition, peptides with less than 40 amino 
acids have the added benefit of being approved as small molecules through the 505 pathway with 
Center for Drug Evaluation and Research (CDER) rather than the 351 pathway with Center for 
Biologics Evaluation and Research (DBER) throughout the FDA approval processes. This avoids 
the additional regulatory hurdles imbedded in the biological pathway and the aggressive biosimilar 
market landscape in the US. Many successful peptide therapeutic candidates have already seen 
success on the market, and the residue length of approved peptide therapeutics has been increasing 
each decade (Figure 44).192  
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Figure 44. Length of peptides entering clinical development, by decade. Peptides with unknown length were 
not included in the average length calculation. Used with permission from Lau, J.L. and M.K. Dunn, 
Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorganic & 
Medicinal Chemistry, 2018. 26(10): p. 2700-2707. 
 
The potential for foldamers, as opposed to natural sequences (as was mostly referred to 
above), to reach the clinical market is still, at this point, a considerable challenge. Even natural 
sequences are limited by concerns of short plasma half-life, challenging bioavailability, 
immunogenicity, a potentially low yielding synthesis and the need for substantially higher 
financial investments (compared to small molecule candidates).184,193 While foldamers often share 
many of these same challenges, they also embody the potential to address them if appropriately 
designed. The open questions of pharmacokinetics and ADME profiles that have yet to be 
examined for most foldamer designs are additional hurdles for the foldamer field but will be 
essential for continued progress toward any medicinal applications.187  
Despite the above open questions, the therapeutic potential of foldamers and other 
unnatural peptides is a subject of much excitement,112,184,194-196 and peptides with unnatural 
modifications are continuing to enter the therapeutic market (Table 5).  
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Table 5. Selective peptide therapeutics approved by the FDA between 2011 and 2017196  
Generic Name Modification 
Macimorelin acetate 
2-Aminoisobutyric acid, D-Trp,  
D- gTrp-CHO 
Abaloparatide 2-Aminoisobutyric acid  
Etelcalcetide 
N-Terminal acetylation; C-terminal 
amidation  
Plecanatide Cyclization by 2 disulfide bridges  
Lixisenatide C-terminal conjugation of polylysine 
Gallium Ga 68 dotatate Cyclization, D-amino acids  
Insulin degludec Lipidation, amino acid elimination 
Peginesatide PEGylation  
 
Progress to overcome limitations of peptide and protein therapeutics is continuing to 
advance. For example, the effect of multiple  to 3 modifications within a peptide epitope was 
analyzed against the immune response for the parent sequence. It was found that antibody 
recognition raised against the parent sequence was suppressed by the periodic  to 3 
modification.197 Work analyzing the immunogenicity of a D-protein antagonist of natural vascular 
endothelial growth factor A (VEGF-A) also found that while the native sequence generated strong 
immune response in mice, the variant was nonimmunogenetic.198 These trends for immunogenicity 
of 3 and D-residue substituted peptides are promising. More data will be necessary to determine 
the extent to which such observations will hold in other systems. In the meantime, studies to predict 
which individuals will have a immune response to a particular drug are ongoing.199 Research into 
expanding the range of potential residues capable of inclusion through ribosomal synthesis is also 
an active area of pursuit.200,201 Still, it is estimated that of the ~70 peptide drugs (defined as less 
than 40 amino acids by the FDA) already on the market, about 85% are produced via synthetic 
rather than recombinant methods – thereby minimizing the common concern that foldamers could 
not be produced on a commercially viable scale.184 
Furthermore as peptides enter the market, a trend exists towards “analog peptides” which 
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are based on natural sequences and contain slight alterations which improve their pharmacology 
profile.192 In 2017, for example, the FDA approved 46 drugs. 12 were biologics and 34 new 
chemical entities (NCE). Of the 34 NCE, six were peptides which spanned the spectrum of 
structural complexity.202 Five of these are produced with SPPS, and three contain an Aib residue.202 
Yet despite this, the structures of these peptides are essentially linear and nowhere near the 
complexity of a tertiary structure. 
The number of potential drug targets has been estimated to be well over 10,000, and a 
recent article cites the characterization of over 14,000 PPI in the human body.203 The reality that 
less than 500 targets are addressed by FDA approved drugs reveals a significant need for new 
therapeutic entities.185 Several review articles detail progress towards the therapeutic space for 
foldamers and other unnatural peptides.196,204,205  
In light of above, the efforts of the foldamer research community to mimic increasingly 
complex peptide structures embodies a wealth of knowledge that holds great potential if applied 
towards pressing barriers. I will continue to watch the field with excitement and high hopes for 
progress.  
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